1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists
By developing TLR7 agonist compounds and antibody conjugates of the 1H-pyrazolo[4,3-d]pyrimidine aromatic system, the problem of the limited effectiveness of existing TLR7 agonists in activating the immune system in cancer immunotherapy has been solved, achieving more effective targeted delivery and synergistic effects with anticancer immunotherapeutic agents, and significantly inhibiting tumor growth.
Patent Information
- Application Number
- CN202180022814.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-28
- Filing Date
- 2021-01-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-01-26
AI Technical Summary
Existing TLR7 agonists have insufficient effect on activating the immune system in cancer immunotherapy, are difficult to effectively target and deliver to the intended target tissues or organs, and lack synergistic effects when used in combination with anticancer immunotherapeutic agents.
Develop compounds with the 1H-pyrazolo[4,3-d]pyrimidine aromatic system as TLR7 agonists, conjugate them with antibodies for targeted delivery to specific tissues, and modulate drug properties through PEGylation to enhance immune responses in combination with anticancer immunotherapeutic agents.
It improved the immune activation effect of TLR7 agonists in cancer immunotherapy, enhanced the synergistic effect with anticancer immunotherapeutic agents, significantly inhibited tumor growth and improved patient symptoms.
Smart Images

Figure CN115643805B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Application Serial No. 63 / 057,675, filed on July 28, 2020, and U.S. Provisional Application Serial No. 62 / 966,098, filed on January 27, 2020; the disclosures of which are incorporated herein by reference. Background Art
[0003] The present disclosure relates to Toll-like receptor 7 ("TLR7") agonists and conjugates thereof, and methods of making and using such agonists and conjugates thereof.
[0004] Toll-like receptors ("TLRs") are receptors that recognize pathogen-associated molecular patterns ("PAMPs"), which are small molecule motifs that are conserved in certain types of pathogens. TLRs can be located on the cell surface or inside the cell. Activation of TLRs by binding to their cognate PAMPs signals the presence of the relevant pathogen (i.e., infection) in the host and stimulates the host's immune system to resist infection. Humans have 10 TLRs, called TLR1, TLR2, TLR3, etc.
[0005] Activation of TLRs by agonists (of which TLR7 is the most studied) can have a positive effect on the role of vaccines and immunotherapeutics in treating a variety of conditions beyond actual pathogen infection by stimulating the overall immune response. Therefore, there is great interest in the use of TLR7 agonists as vaccine adjuvants or as enhancers in cancer immunotherapy. See, for example, Vasilakos and Tomai 2013, Sato-Kaneko et al. 2017, Smits et al. 2008, and Ota et al. 2019.
[0006] TLR7 (an intracellular receptor located on the endosomal membrane) recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces the secretion of type I interferons (such as IFNα and IFNβ) (Lund et al. 2004). TLR7 has two binding sites, one for single-stranded RNA ligands ( et al. 2007), and one for small molecules such as guanosine (Zhang et al. 2016).
[0007] TLR7 can bind to and be activated by guanosine-like synthetic agonists based on the 1H-imidazo[4,5-c]quinoline skeleton, such as imiquimod, resiquimod, and gardiquimod. For a review of small molecule TLR7 agonists, see Cortez and Va 2018.
[0008]
[0009] Synthetic TLR7 agonists based on the pteridinone molecular scaffold are also known, as exemplified by vesatolimod (Desai et al. 2015).
[0010]
[0011] Other synthetic TLR7 agonists based on a purine-like skeleton, often according to the general formula (A), have been disclosed:
[0012]
[0013] wherein R, R' and R" are structural variables, wherein R" typically contains an unsubstituted or substituted aromatic or heteroaromatic ring.
[0014] Publications of bioactive molecules with a purine-like backbone and their use in treating conditions such as fibrosis, inflammatory disorders, cancer, or pathogenic infections include: Akinbobuyi et al. 2015 and 2016; Barberis et al. 2012; Carson et al. 2014; Ding et al. 2016, 2017a and 2017b; Graupe et al. 2015; Hashimoto et al. 2009; He et al. 2019a and 2019b; Holldack et al. 2012; Isobe et al. 2009a and 2012; Poudel et al. 2019a and 2019b; Pryde 2010; and Young et al. 2019.
[0015] The group R" can be a pyridyl group: Bonfanti et al. 2015a and 2015b; Halcomb et al. 2015; Hirota et al. 2000; Isobe et al. 2002, 2004, 2006, 2009a, 2009b, 2011 and 2012; Kasibhatla et al. 2007; Koga-Yamakawa et al. 2013; Musmuca et al. 2009; Nakamura 2012; Ogita et al. 2007; and Yu et al. 2013.
[0016] There are published texts of related molecules in which the 6,5-fused ring system of formula (A) (i.e., a pyrimidine six-membered ring fused to an imidazole five-membered ring) is modified. (a) Dellaria et al. 2007, Jones et al. 2010 and 2012, and Pilatte et al. 2017 disclose compounds in which the pyrimidine ring is replaced by a pyridine ring. (b) Chen et al. 2011, Coe et al. 2017, Poudel et al. 2020a and 2020b, and Zhang et al. 2018 disclose compounds in which the imidazole ring is replaced by a pyrazole ring. (c) Cortez et al. 2017 and 2018; Li et al. 2018; and McGowan et al. 2016a, 2016b and 2017 disclose compounds in which the imidazole ring is replaced by a pyrrole ring.
[0017] Bonfanti et al. 2015b and 2016 and Purandare et al. 2019 disclosed TLR7 modulators with macrocycles spanning two rings of the purine moiety:
[0018] TLR7 agonists can be conjugated to a partner molecule, which can be, for example, a phospholipid, poly(ethylene glycol) ("PEG"), an antibody, or another TLR (typically TLR2). Exemplary publications include: Carson et al. 2013, 2015, and 2016, Chan et al. 2009 and 2011, Cortez et al. 2017, Gadd et al. 2015, Lioux et al. 2016, Maj et al. 2015, Vernejoul et al. 2014, and Zurawski et al. 2012. A frequent conjugation site is at the R" group of formula (A).
[0019] Jensen et al. 2015 disclosed the use of cationic lipid vehicles for the delivery of TLR7 agonists.
[0020] Some TLR7 agonists (including resiquimod) are dual TLR7 / TLR8 agonists. See, e.g., Beesu et al. 2017, Embrechts et al. 2018, Lioux et al. 2016, and Vernejoul et al. 2014.
[0021] Full citations for documents cited herein by first author or inventor and year are listed at the end of this specification. Summary of the invention
[0022] The present description relates to compounds having a 1H-pyrazolo[4,3d]pyrimidine aromatic system, which have activity as TLR7 agonists.
[0023]
[0024] In one aspect, a compound having a structure according to Formula I is provided.
[0025]
[0026] in
[0027] Each X 1 Independently N or CR 2 ;
[0028] X 2 is O, CH2, NH, S or N(C1-C3 alkyl);
[0029] R 1 is (C1-C5 alkyl),
[0030] (C2-C5 alkenyl),
[0031] (C1-C8 Alkanediyl) 0-1 (C3-C6 cycloalkyl),
[0032] (C2-C8 alkanediyl)OH,
[0033] (C2-C8 alkanediyl)O(C1-C3 alkyl),
[0034] (C1-C4 alkanediyl)0-1(5-6 membered heteroaryl),
[0035] (C1-C4 alkanediyl)0-1-phenyl,
[0036] (C1-C4 alkanediyl)CF3,
[0037] (C2-C8 alkanediyl)N[C(=O)](C1-C3 alkyl),
[0038] or
[0039] (C2-C8 alkanediyl)NR x R y ;
[0040] Each R 2 are independently H, O(C1-C3 alkyl), S(C1-C3 alkyl), SO2(C1-C3 alkyl), C1-C3 alkyl, O(C3-C4 cycloalkyl), S(C3-C4 cycloalkyl), SO2(C3-C4 cycloalkyl), C3-C4 cycloalkyl, Cl, F,
[0041] CN or [C(=O)]0-1NR x R y ;
[0042] R 4 It is NH2,
[0043] NH(C1-C5 alkyl),
[0044] N(C1-C5 alkyl)2,
[0045] NH(C1-C4 alkanediyl)0-1(C3-C8 cycloalkyl),
[0046] N(C3-C6 cycloalkyl)2,
[0047] or
[0048] A section with the following structure:
[0049]
[0050] R 5 is H, C1-C5 alkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, halo, O(C1-C5 alkyl), (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl), phenyl, NH(C1-C5 alkyl), 5- or 6-membered heteroaryl,
[0051]
[0052] R x and R y are independently H or C1-C3 alkyl or R x and R y Combined with the nitrogen to which they are bonded, to form a 3- to 7-membered heterocyclic ring; and
[0053] m is 0 or 1;
[0054] Among them, 1 , R 2 , R 4 and R 5 middle
[0055] Alkyl, alkanediyl, cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or a moiety of the formula:
[0056]
[0057] Optionally substituted with one or more substituents selected from the group consisting of OH, halo, CN, (C1-C3 alkyl), O(C1-C3 alkyl), C(═O)(C1-C3 alkyl), SO2(C1-C3 alkyl), NR x R y , (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl);
[0058] and
[0059] Alkyl, alkanediyl, cycloalkyl or a cyclic portion of the formula:
[0060]
[0061] Can have CH2 groups replaced by: O, SO2, CF2, C(=O), NH,
[0062] N[C(=O)] 0-1 (C1-C3 alkyl),
[0063] N[C(=O)] 0-1 (C1-C4 alkanediyl)CF3,
[0064] N[C(=O)] 0-1 (C1-C4 alkanediyl)OH,
[0065] or
[0066] N[C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 (C3-C5 cycloalkyl).
[0067] The compounds disclosed herein have activity as TLR7 agonists, and some compounds can be conjugated with antibodies for targeted delivery to target tissues or organs of intended action. They can also be pegylated to adjust their pharmaceutical properties.
[0068] The compounds disclosed herein, or their conjugates, or their PEGylated derivatives, can be used to treat subjects suffering from a condition amenable to treatment by activation of the immune system by administering to such subjects a therapeutically effective amount of such compounds, or their conjugates, or their PEGylated derivatives, especially in combination with vaccines or cancer immunotherapeutics. DETAILED DESCRIPTION
[0069] Compound
[0070] In one aspect, in formula (I), the following moiety:
[0071] yes (i.e., m is 0).
[0072] In one aspect, the compounds of the present disclosure are according to formula (Ia), wherein R 1 , R 2 , R 4 and R 5 is as defined with respect to formula (I):
[0073]
[0074] In another aspect, the compounds of the present disclosure are according to formula (Ib), wherein R 1 , R 4 and R 5 is as defined with respect to formula (I):
[0075]
[0076] In formula (Ib), R 5 Preferably H.
[0077] In another aspect, the present disclosure provides compounds having a structure according to Formula (Ib), wherein
[0078] R 1 yes
[0079]
[0080] R 4 yes
[0081]
[0082] and
[0083] R 5 It is H, Me or F.
[0084] Preferably, R 1 Selected from the following group ("preferred R 1 Group"):
[0085]
[0086] In another embodiment, R 1 yes
[0087]
[0088] Group R 2 Examples include (of which the first is preferred)
[0089]
[0090] Group R 4 Examples include:
[0091]
[0092]
[0093] Preferably, R 4 Selected from the following group ("preferred R 4 Group"):
[0094]
[0095] Suitable groups R 5 Examples are H,
[0096]
[0097] Preferably, R 5 It is H or Me.
[0098] Preferably, R 4 Selected from the preferred R 4 Group, in combination with: selected from the preferred R 3 Group R 3 ; Selected from preferred R 1 Group R 1 , and R 5 Equal to H or Me.
[0099] By way of example and not limitation, a portion of the following formula:
[0100]
[0101] include
[0102]
[0103]
[0104] Some of the above exemplary portions of the following formulae:
[0105]
[0106] Having optional substituents and / or optionally having one or more CH2 groups replaced by O, SO2, etc., as described above in the Summary of the Invention.
[0107] Specific examples of compounds disclosed herein are shown in Table A below. The table also provides data related to biological activity: human TLR7 agonism reporter assay and / or induction of CD69 gene in human whole blood, determined according to the procedures provided below. The rightmost column contains analytical data (mass spectrometry, LC / MS retention time and NMR). In one embodiment, the compounds of the present disclosure have (a) a human TLR7 (hTLR7) reporter assay EC less than 1,000 nM. 50 values and (b) human whole blood (hWB) CD69 induced EC less than 1,000 nM 50 (When the measurement was performed multiple times, the reported value is the average value.)
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119] Pharmaceutical compositions and administration
[0120] In another aspect, a pharmaceutical composition is provided, comprising a compound as disclosed herein or a conjugate thereof formulated with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as biologics or small molecule drugs. The pharmaceutical composition may be administered together with another therapeutic agent (especially an anticancer agent) in a combination therapy.
[0121] The pharmaceutical composition may include one or more excipients. Available excipients include carriers, surfactants, thickeners or emulsifiers, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrants, lubricants, sweeteners, preservatives, isotonic agents and combinations thereof. Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th edition (Lippincott Williams & Wilkins 2003) teaches the selection and use of suitable excipients.
[0122] Preferably, the pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (for example, by injection or infusion). According to the route of administration, the active compound can be coated in the material to protect the compound from the effects of acid and other natural conditions that may inactivate it. The phrase "parenteral administration" means the mode of administration except enteral administration and topical administration, usually by injection, and includes but is not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via non-parenteral routes, such as external, epidermal or mucosal administration routes, for example, intranasal, oral, vaginal, rectal, sublingual or topical.
[0123] The pharmaceutical composition may be in the form of a sterile aqueous solution or dispersion. They may also be formulated as microemulsions, liposomes, or other ordered structures suitable for achieving high drug concentrations. The composition may also be provided in the form of a lyophilisate (for reconstitution in water prior to administration).
[0124] The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the subject being treated and the particular mode of administration and will generally be that amount of the composition that produces a therapeutic effect. Typically, in terms of percentage, this amount will range from about 0.01% to about 99% of the active ingredient, preferably from about 0.1% to about 70%, most preferably from about 1% to about 30% of the active ingredient, combined with a pharmaceutically acceptable carrier.
[0125] The dosage regimen is adjusted to provide the therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" refers to physically discrete units suitable as unit dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.
[0126] The range of the dosage is from about 0.0001 to 100 mg / kg host body weight and more generally 0.01 to 5 mg / kg host body weight. For example, the dosage can be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight or 10 mg / kg body weight or in the range of 1-10 mg / kg or alternatively 0.1 to 5 mg / kg. An exemplary treatment regimen is once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every 3 to 6 months. A preferred dosage regimen includes using one of the following dosing times via intravenous administration of 1 mg / kg body weight or 3 mg / kg body weight: (i) every four weeks, for six doses, then every three months; (ii) every three weeks; (iii) once 3 mg / kg body weight, then 1 mg / kg body weight every three weeks. In some methods, the dosage is adjusted to reach a plasma antibody concentration of about 1-1000 μg / mL and about 25-300 μg / mL in some methods.
[0127] A "therapeutically effective dose" of a compound of the invention preferably results in a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or the prevention of injury or disability caused by disease distress. For example, for the treatment of tumor-bearing subjects, a "therapeutically effective dose" preferably inhibits tumor growth by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, still more preferably at least about 80%, relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can reduce tumor size or otherwise improve symptoms in a subject, who is typically a human, but can be another mammal. In the case of two or more therapeutic agents administered in a combination therapy, a "therapeutically effective amount" refers to the efficacy of the combination as a whole, rather than the efficacy of each agent individually.
[0128] The pharmaceutical composition can be a controlled release or sustained release formulation, including implants, transdermal patches and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.
[0129] The therapeutic composition can be administered via a medical device such as (1) a needle-free subcutaneous injection device; (2) a microinfusion pump; (3) a transdermal device; (4) an infusion device; and (5) an osmotic device.
[0130] In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution in vivo. For example, to ensure that the therapeutic compounds of the invention cross the blood-brain barrier, they can be formulated in liposomes, which can additionally contain targeting moieties to enhance selective transport to specific cells or organs.
[0131] Industrial applicability and use
[0132] The TLR7 agonist compounds disclosed herein can be used to treat diseases or conditions that can be ameliorated by activating TLR7.
[0133] In one embodiment, TLR7 agonists are used in combination with anti-cancer immunotherapeutics (also referred to as immuno-oncology agents). Anti-cancer immunotherapeutics work by stimulating the body's immune system to attack and destroy cancer cells, especially by activating T cells. The immune system has many checkpoint (regulatory) molecules to help maintain the balance between its attack on legitimate target cells and normal cells that prevent it from attacking health. Some molecules are stimulants (up-regulators), which means that their participation promotes T cell activation and enhances immune response. Other molecules are inhibitors (down-regulators or inhibitors), which means that their participation inhibits T cell activation and alleviates immune response. The combination of agonistic immunotherapeutics with stimulatory checkpoint molecules can lead to the latter's activation and immune response enhancement for cancer cells. On the contrary, the combination of antagonistic immunotherapeutics with inhibitory checkpoint molecules can prevent the immune system from being down-regulated by the latter and help maintain a strong response for cancer cells. Examples of stimulatory checkpoint molecules are B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H. Examples of inhibitory checkpoint molecules are CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galectin 9, CEACAM-1, BTLA, CD69, galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, CD96, and TIM-4.
[0134] Regardless of the mode of action of the anti-cancer immunotherapeutic agent, its effectiveness can be improved by generally regulating the immune system (such as by activating TLR7). Therefore, in one embodiment, this specification provides a method for treating cancer, comprising administering an anti-cancer immunotherapeutic agent and a therapeutically effective combination of a TLR7 agonist as disclosed herein to a patient suffering from such cancer. The administration time may be simultaneous, sequential or alternating. The administration mode may be systemic or local. The TLR7 agonist may be delivered in a targeted manner via a conjugate.
[0135] Cancers that may be treated by combination therapy as described above include acute myeloid leukemia, adrenocortical carcinoma, Kaposi's sarcoma, lymphoma, anal cancer, appendix cancer, teratoid / rhabdoid tumors, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumors, carcinoid tumors, heart tumors, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasms, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, nasal glioma, Ewing's sarcoma, Eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, germ cell tumors, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopharyngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myeloid leukemia, lip and oral cavity cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penis cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, laryngeal cancer, thyroid cancer, urethra cancer, uterus cancer, vaginal cancer, and vulvar cancer.
[0136] Anti-cancer immunotherapeutic agents that can be used in the combination therapy as disclosed herein include: AMG 557, AMP-224, atezolizumab, avelumab, BMS 936559, cemiplimab, CP-870893, dacetuzumab, durvalumab, enoblituzumab, galiximab, IMP321, ipilimumab, lucatumumab, MEDI-570, MEDI-6383, MEDI-6469, muromonab-CD3, nivolumab, pembrolizumab, pidilizumab, spartalizumab, tremelimumab, urelumab, utomilumab, varlilumab, vonlerolizumab. Table B below lists one or more of their alternative names (trade names, former names, research codes or synonyms) and their respective target checkpoint molecules.
[0137]
[0138]
[0139] In one embodiment of the combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody. The cancer can be lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial carcinoma (including bladder cancer), gastric cancer, hepatocellular carcinoma or colorectal cancer.
[0140] In another embodiment of combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-CTLA-4 antibody, preferably ipilimumab.
[0141] In another embodiment of the combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-PD-1 antibody, preferably nivolumab or pembrolizumab.
[0142] The TLR7 agonists disclosed herein may also be used as vaccine adjuvants.
[0143] The practice of the present invention may be further understood by reference to the following examples, which are provided by way of illustration and not limitation.
[0144] Analytical procedures
[0145] NMR
[0146] The following conditions were used to obtain proton nuclear magnetic resonance (NMR) spectra: NMR spectra were collected in a 400Mz or 500Mhz Bruker instrument using DMSO-d6 or CDCl3 as solvent and internal standard. Raw NMR data were analyzed by using ACD Spectrus version 2015-01 or MestReNova software from ADC Labs.
[0147] Chemical shifts are reported as low-field parts per million (ppm) relative to internal tetramethylsilane (TMS) or relative to the TMS position inferred by deuterated NMR solvents. Apparent multiplicities are reported as: singlet-s, doublet-d, triplet-t, quartet-q, or multiplet-m. Peaks showing broadening are further denoted as br. Integration is approximate. It should be noted that integral intensity, peak shape, chemical shift, and coupling constants may depend on solvent, concentration, temperature, pH, and other factors. In addition, peaks that overlap or exchange with water or solvent peaks in the NMR spectrum may not provide reliable integral intensity. In some cases, NMR spectra can be obtained using water peak suppression, which may cause overlapping peaks to be invisible or have a changed shape and / or integration.
[0148] Liquid chromatography
[0149] The following LC method was used:
[0150] LC / MS Method A. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 0 min at 6% B, 6%-46% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal.
[0151] LC / MS Method B. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 11% B for 0 min, 11%-51% B over 25 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal.
[0152] LC / MS method C. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 2% B for 0 min, 2%-42% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal.
[0153] LC / MS method D. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 5% B for 0 min, 5%-45% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS and UV signals.
[0154] LC / MS method E. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 3% B for 0 min, 3%-43% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS and UV signals.
[0155] LC / MS method F. Column: Acquity BEH C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: water with 0.05% TFA; Mobile phase B: acetonitrile with 0.05% TFA; Gradient: 2% B to 98% B over 1 min, then hold at 98% B for 0.5 min; Flow rate: 0.8 mL / min; Detection: MS and UV.
[0156] LC / MS Method G. Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 10 mM ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with 10 mM ammonium acetate); Temperature: 50°C; Gradient: 0% B to 100% B over 3 min, then hold at 100% B for 0.50 min; Flow rate: 1 mL / min.
[0157] LC / MS method H. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 5% B for 0 min, 5%-45% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal.
[0158] LC / MS Method I. Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with ammonium acetate); Mobile phase B: 95:5 acetonitrile:water (with ammonium acetate); Gradient: 0% B for 0 min, 0-40% B over 20 min, then 100% B for 4 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal.
[0159] LC / MS method J. Column: BEH C18 2.1 x 50 mm; Mobile phase A: water with 0.05% TFA; Mobile phase B: acetonitrile with 0.05% TFA; Temperature: 50°C; Gradient: 2%-98% B over 1.0 min, then hold at 98% B for 0.50 min; Flow rate: 0.8 mL / min. Detection: MS and UV (220 nm).
[0160] LC / MS method K. Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.1% trifluoroacetic acid); Mobile phase B: 95:5 acetonitrile:water (with 0.1% trifluoroacetic acid); Temperature: 50°C; Gradient: 0% B to 100% B over 3 min, then hold at 100% B for 0.50 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).
[0161] LC / MS method L. Column: BEH C18 2.1 x 50 mm; Mobile phase A: 95:5 H2O:ACN (containing 0.01 M NH4OAc); Mobile phase B: 5:95 H2O:ACN (containing 0.01 M NH4OAc); Temperature: 50°C; Gradient: 5%-95% B over 1 min; Flow rate: 0.8 mL / min.
[0162] Synthesis - General Procedure
[0163] In general, the procedures disclosed herein produce a mixture of regioisomers alkylated at the 1H or 2H position of the pyrazolopyrimidine ring system (which are also referred to as N1 and N2 regioisomers, respectively, implying the alkylated nitrogen). For simplicity, the N2 regioisomers are not shown, but it is understood that they are present in the initial product mixture and are separated later, for example, by preparative HPLC.
[0164]
[0165] The mixture of regioisomers may be separated early in the synthesis and the remaining synthetic steps carried out with the 1H regioisomer, or alternatively, the synthesis may be carried forward with the mixture of regioisomers and separated later as desired.
[0166] The compounds of the present disclosure may be prepared by a variety of methods well known to those skilled in the art of synthetic organic chemistry. These methods include those described below or variations thereof. Preferred methods include, but are not limited to, those described below in the following schemes. The schemes are intended to be general, but in some cases, for convenience, features (e.g., methyl esters or specific regioisomers) may be specifically depicted.
[0167] Solution 1
[0168]
[0169] In scenario 1 and its other occurrences, R a It can be, for example
[0170] or other suitable part. In Scheme 1 and any other occurrence thereof, R b is, for example, C1-C3 alkyl. In Scheme 1 and other occurrences thereof, R c NHR d is a primary or secondary amine. During the synthesis process, R a , R b , R c and / or R d It may have a functional group masked by a protecting group which is removed when appropriate.
[0171] Compound 10 can be prepared via the synthetic sequence outlined above in Scheme 1. Reduction of nitropyrazole 1 provides compound 2, which is then cyclized with 1,3-bis(methoxycarbonyl)-2-methyl-2-thioisourea to give hydroxypyrazolopyrimidine 3. Amine R is introduced using BOP / DBU coupling conditions. aNH2 followed by bromination with NBS (step 4) afforded bromopyrazolopyrimidine 5. Alkylation with benzyl halide 6 afforded a mixture of N1 and N2 products, which were separated to afford N1 intermediate 7. Catalytic hydrogenation (step 6) followed by one-pot methyl carbamate deprotection and saponification afforded intermediate acid 9. Acid 9 was coupled with amines using HATU (or EDC) conditions to afford target compound 10. (Alkylation of brominated intermediate 5 in step 5 afforded a better N1 / N2 product ratio than alkylation of unbrominated intermediate 4).
[0172] Solution 2
[0173]
[0174] Alternatively, intermediate 9 can be obtained using the route described in Scheme 2 above. Intermediate 3 was brominated using NBS followed by alkylation to give intermediate ester 12. Amination was then performed using BOP coupling conditions to give intermediate 7. Catalytic hydrogenation followed by saponification and methyl carbamate deprotection gave intermediate 9.
[0175] Solution 3
[0176]
[0177]
[0178] An alternative route to intermediate 8 begins with alkylation of nitropyrazole 1 with benzyl halide 6 to give benzyl pyrazole 13. Reduction of the nitro group followed by cyclization with 1,3-bis(methoxycarbonyl)-2-methyl-2-thioisourea gives hydroxypyrazolopyrimidine 15, which is converted to the appropriate amine derivative 8 using BOP / DBU conditions. This is illustrated in Scheme 3 above.
[0179] Solution 4
[0180]
[0181] Another alternative route to the target compound is shown above in Scheme 4. Starting from intermediate 15, the ester group was hydrolyzed and the methyl carbamate was removed using sodium hydroxide to give the acid 16. Amide coupling using HATU (or EDC) gave the amide 17, followed by amination using BOP / DBU conditions to give the target molecule 10.
[0182] Synthesis - Specific Examples
[0183] To further illustrate the foregoing, the following non-limiting, exemplary synthetic schemes are included. Variations of these embodiments within the scope of the claims are within the capabilities of those skilled in the art and are considered to fall within the scope of this disclosure. The reader should recognize that a skilled artisan provided with this disclosure and who is a person skilled in the relevant art will be able to prepare and use the compounds disclosed herein without exhaustive examples.
[0184] Analytical data for compounds numbered 100 and above can be found in Table A.
[0185] Example 1-Compound 111
[0186]
[0187] Step 1. A solution of NBS (6.94 g, 39.0 mmol) in DMF (20 mL) was added to a stirred suspension of methyl (7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (10 g, 37.8 mmol) in DMF (80 mL). The reaction mixture was stirred at room temperature for 90 min, and poured into water (400 mL), and stirred for 5 min. The product was collected by filtration, washed with water (200 mL), and air-dried overnight to give methyl (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (7.5 g, 21.85 mmol, 57.8% yield) as a solid.
[0188] LC-MS (ES, m / z): [M+H] + =343.0,345.0.
[0189] 1 H NMR(400MHz,DMSO-d6)δ12.87(br s,1H),9.80(s,1H),7.56(br s, 1H), 3.62 (s, 3H), 3.54 (q, J = 6.6Hz, 2H), 1.62 (quin, J = 7.2Hz, 2H), 1.40 (dq, J = 14.8, 7.4Hz, 2H), 0.94 (t, J = 7.4Hz, 3H).
[0190] Step 2. At 0 ° C, a solution of methyl 4-(bromomethyl)-3-methoxybenzoate (1.861 g, 7.18 mmol) in DMF (5 mL) was added to a stirred suspension of (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.9 g, 8.45 mmol) and CsCO (3.30 g, 10.14 mmol) in DMF (35 mL) over 5 min in batches. The reaction mixture was heated to room temperature, stirred overnight, poured into saturated NaHCO solution (300 mL), and extracted with EtOAc (3x70 mL). The combined organic phases were washed with saline (4x 50 mL), dried (MgSO), filtered and concentrated. Flash chromatography (SiO2 column, 0 to 50% EtOAc in hexanes) afforded methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (1.400 g, 2.69 mmol, 31.8% yield) as a solid.
[0191] LC-MS (ES, m / z): [M+H] + =521.2,523.2.
[0192] 1 H NMR (400MHz, DMSO-d6) δ9.88(s,1H),7.54-7.48(m,2H),7.32(t,J=5.6Hz,1H),6.79(d,J=7.7Hz,1H),5.78(s,2H),3.86(s ,3H),3.85(s,3H),3.63(s,3H),3.52(q,J=6.6Hz,2H),1.56(quin,J=7.3Hz,2H),1.28-1.15(m,2H),0.84(t,J=7.4Hz,3H).
[0193] Step 3. Methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (1.400 g, 2.69 mmol) was suspended in EtOH (80 mL). 10% Pd / C (200 mg) was added. The reaction vessel was evacuated and purged with H2 six times. The reaction mixture was stirred under H2 atmosphere for 1 h. The reaction vessel was evacuated, purged with N2, and purified by CELITE TMMedium filtration (washed with EtOH (100mL)). The filtrate is evaporated to dryness, and the residue is dissolved in dioxane (10mL). NaOH (3.22mL, 16.11mmol) is added, and the reaction mixture is stirred for 2h at 80 ° C and cooled to room temperature. The reaction mixture is diluted with water (10mL) and acidified with 5N HCl, and dioxane is removed by evaporation. The residue is diluted with more water (20mL), and the product is collected by filtration and washed with acetonitrile after water to obtain 4- ((5- amino -7- (butylamino) -1H- pyrazolo [4,3-d] pyrimidin -1- yl) methyl) -3- methoxybenzoic acid (900mg, 2.430mmol, 90% yield) as a white solid.
[0194] LC-MS (ES, m / z): [M+H] + 371.2.
[0195] Step 4. A 20 mL scintillation vial was charged with 4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (30 mg, 0.081 mmol), HATU (37.0 mg, 0.097 mmol), DMF (2 mL) and N,N-dimethylethane-1,2-diamine (7.14 mg, 0.081 mmol). DIPEA (0.035 mL, 0.202 mmol) was added. The reaction mixture was stirred at 65 °C overnight. The crude product was purified by preparative LC / MS under the following conditions: column: XBridgeC18, 200mm x 19mm, 5μm particles; mobile phase A: 5:95 acetonitrile: water (with ammonium acetate); mobile phase B: 95:5 acetonitrile: water (with ammonium acetate); gradient: 0 min at 6% B, 20 min 6%-46% B, then 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 111 (3.3 mg, 0.0075 mmol, 9.3%).
[0196] The following compounds were prepared similarly: Compound 102, Compound 103, Compound 104, Compound 105, Compound 106, Compound 107, Compound 108, Compound 109, Compound 110, Compound 112, Compound 113, Compound 114, Compound 115 and Compound 116.
[0197] Example 2-Compound 124
[0198]
[0199] Step 1. (3-methylenecyclobutyl) methylamine hydrochloride (4.5g, 33.7mmol) is suspended in DCM (30mL). Add DIPEA (17.65mL, 101mmol), then add Boc-anhydride (8.60mL, 37.0mmol). The reaction mixture is stirred at room temperature for 2h, poured into saturated NaHCO solution (100mL), and extracted with DCM (3x70mL). The organic phase merged is saturated NaHCO solution (50mL) and salt solution (4x 50mL) are washed, dried (MgSO), filtered and concentrated. Flash chromatography (SiO column, 0 to 10% EtOAc hexane solution) obtains ((3-methylenecyclobutyl) methyl) tert-butyl carbamate (4.73g, 23.98mmol, 71.2% yield) as oil.
[0200] 1 H NMR (400MHz, CDCl3) δ4.77 (quin, J = 2.3Hz, 2H), 3.20 (br d, J = 6.6Hz, 2H), 2.81-2.72 (m, 2H), 2.48-2.32 (m, 3H), 1.45 (s, 9H).
[0201] Step 2. solution of tert-butyl ((3-methylenecyclobutyl) methyl) carbamate (2.1g, 10.64mmol) in DCE (20mL) is cooled in an ice bath. Add chloroiodomethane (2.318mL, 31.9mmol), then add diethyl zinc (15.97mL, 15.97mmol) in batches over 10min. After addition is complete, allow the reaction mixture to be slowly heated to room temperature and stir for 3h. Carefully add water (5mL) to quench the reaction. Reactant mixture is acidified with 1N HCl (10mL) and extracted with EtOAc (3x40mL). The organic phase merged is washed with salt water (10mL), dried (MgSO ), filtered and concentrated. Flash chromatography (SiO2 column, 0 to 18% EtOAc in hexanes) afforded tert-butyl (spiro[2.3]hexan-5-ylmethyl)carbamate (812 mg, 3.84 mmol, 36.1% yield) as an oil.
[0202] 1 H NMR(400MHz,CDCl3-d)δ4.53(br s,1H),3.25(br d,J=5.9Hz,2H),2.53(dt,J=14.6,7.1Hz,1H),2.18-2.11(m,2H),1.81(dd,J=12.4,6.1Hz,2H),1.45(s,9H),0.39(s,4H).
[0203] Step 3. tert-Butyl (spiro[2.3]hex-5-ylmethyl)carbamate (800 mg, 3.79 mmol) was dissolved in dioxane (3 mL) and HCl in dioxane (2.84 mL, 11.36 mmol) was added. The reaction mixture was stirred at room temperature overnight and evaporated to dryness to give (3-(2-chloroethyl)cyclobutyl)methanamine hydrochloride (680 mg, 3.7 mmol, 97% yield) as a solid.
[0204] 1 H NMR(400MHz,DMSO-d6)δ7.97(br s,4H),3.54-3.39(m,1H),3.03-2.91(m,1H),2.91-2.79(m,2H),2.54-2.45(m,3H),2.45-2.2 6(m,3H),2.23-2.15(m,1H),1.91-1.79(m,3H),0.98(t,J=7.2Hz,2H),0.92(t,J=7.3Hz,2H).
[0205] Step 4. by Cs CO (11.42g, 35.1mmol) is added to the stirring solution of 4-nitro-1H-pyrazole-5-methyl-formiate (5g, 29.2mmol) in DMF (30mL).After cooling in an ice bath, a solution of 4-(bromomethyl)-3-methoxybenzoic acid methyl ester (7.57g, 29.2mmol) in DMF (20mL) is added in batches through 5min. Allow reaction mixture to be slowly heated to room temperature, stir overnight, pour in water (150mL), and extract with EtOAc (3x 70mL). The organic phase merged is washed with salt water (4x 50mL), dried (MgSO ), filtered and concentrated. Flash chromatography (SiO2 column, 0 to 50% EtOAc in hexanes) afforded methyl 1-(2-methoxy-4-(methoxycarbonyl)benzyl)-4-nitro-1H-pyrazole-5-carboxylate (1.012 g, 2.90 mmol, 9.92% yield) as a solid.
[0206] LC-MS (ES, m / z): [M+H] + 350.1.
[0207] 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),7.57(d,J=7.6Hz,1H),7.50(s,1H),7.27(d,J=7.9Hz,1H),5.53(s,2H),3.96(s,3H),3.86(s,3H),3.82(s,3H).
[0208] Step 5. 1-(2-methoxy-4-(methoxycarbonyl)benzyl)-4-nitro-1H-pyrazole-5-formic acid methyl ester (2g, 5.73mmol) is suspended in EtOH (100mL). 10% Pd / C (100mg) is added. The reaction vessel is evacuated and purged with hydrogen six times. The reaction mixture is stirred overnight under a hydrogen atmosphere and filtered through CELITETM medium (washed with EtOH (100mL)). The filtrate is evaporated to dryness, so as to obtain 4-amino-1-(2-methoxy-4-(methoxycarbonyl)benzyl)-1H-pyrazole-5-formic acid methyl ester (1.764g, 5.52mmol, 96% yield) as a solid.
[0209] LC-MS (ES, m / z): [M+H] + 320.1.
[0210] 1 H NMR (400MHz, DMSO-d6) δ7.50 (s, 1H), 7.46 (d, J = 7.7Hz, 1H), 7.18 (s, 1H), 6.42 (d ,J=7.9Hz,1H),5.55(s,2H),5.14(s,2H),3.91(s,3H),3.84(s,3H),3.70(s,3H).
[0211] Step 6. 4-amino-1-(2-methoxy-4-(methoxycarbonyl)benzyl)-1H-pyrazole-5-carboxylic acid methyl ester (1.75g, 5.48mmol) was suspended in MeOH (60mL). 1,3-bis(methoxycarbonyl)-2-methyl-2-thioisourea (1.243g, 6.03mmol) was added, followed by AcOH (1.882mL, 32.9mmol). The reaction mixture was stirred at room temperature for 1h. TFA (2mL, 26mmol) was added, and the reaction mixture was stirred overnight. Sodium methoxide (23.69g, 110mmol) was added, and the reaction mixture was stirred at room temperature for 4h. The reaction mixture was filtered, and the filtrate was acidified with AcOH. MeOH was evaporated, and the resulting precipitate was collected by filtration and suspended in dioxane (10mL). Sodium hydroxide (1.896mL, 9.48mmol) was added, and the reaction mixture was stirred at 80°C for 4h. After cooling, the reaction mixture was neutralized with HCl and the organic phase was evaporated to dryness. The product was collected and washed with water to give 4-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (250 mg, 0.793 mmol, 13% yield) as a solid.
[0212] LC-MS (ES, m / z): [M+H] + 316.1.
[0213] Step 7. A 20 mL scintillation vial was charged with 4-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (250 mg, 0.793 mmol), HATU (332 mg, 0.872 mmol), DIPEA (0.277 mL, 1.586 mmol) and DMF (5 mL). The reaction mixture was stirred at 50 °C overnight, cooled, filtered and purified by reverse phase flash chromatography (C 18 The product was purified by column (4% paraformaldehyde, 0 to 30% acetonitrile in water with 0.05% formic acid) to afford 4-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (230 mg, 0.559 mmol, 70.5% yield) as a solid.
[0214] LC-MS (ES, m / z): [M+H] + 412.3.
[0215] 1 H NMR (400MHz, DMSO-d6) δ8.26-8.19(m,1H),7.56(s,1H),7.40(d,J=1.3Hz,1H),7.31-7.27(m, 1H),6.52(d,J=7.9Hz,1H),6.08(s,2H),5.62(s,2H),3.87(s,3H),3.84-3.75(m,1H),2.99(br d,J=11.7Hz,2H),2.36(s,4H),1.82(br d,J=10.3Hz,2H),1.75-1.54(m,2H).
[0216] Step 8. A 20 mL scintillation vial was charged with 4-((5-amino-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.486 mmol), (3-(2-chloroethyl)cyclobutyl)methanamine hydrochloride (224 mg, 1.215 mmol), BOP (322 mg, 0.729 mmol), DBU (0.220 mL, 1.458 mmol) and DMSO (5 mL). The reaction mixture was stirred at room temperature for 2 h, diluted with water (2 mL), filtered and purified by reverse phase flash chromatography (C 18The product was purified by HPLC-MS / MS (HPLC-MS / MS: 50444 / 0.90444) using a Celite® column, 0 to 75% MeCN in water with 10 mM TEAA) to afford 4-((5-amino-7-(((3-(2-chloroethyl)cyclobutyl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (227 mg, 0.420 mmol, 86% yield) as a brown solid.
[0217] LC-MS (ES, m / z): [M+H] + 541.4.
[0218] Step 9. A 20 mL scintillation vial was charged with 4-((5-amino-7-(((3-(2-chloroethyl)cyclobutyl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (150 mg, 0.277 mmol), sodium acetate (227 mg, 2.77 mmol) and DMF (3 mL). The reaction mixture was stirred at 100 °C for 4 days, cooled, and diluted with water (3 mL). Reverse phase flash chromatography (C 18 Column, 0 to 65% acetonitrile in water (containing 0.05% TFA)) for purification to provide an intermediate. The intermediate was dissolved in EtOH (5 mL) and 10% Pd / C (10 mg) was added. The reaction vessel was evacuated and purged with hydrogen six times. Then, under a hydrogen atmosphere, its contents were stirred for 2 h. The reaction mixture was filtered and evaporated to dryness. The crude product was purified via preparative LC / MS using the following conditions: column: XBridgeC18, 200 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile: water (containing ammonium acetate); mobile phase B: 95:5 acetonitrile: water (containing ammonium acetate); gradient: 0 minutes at 11% B, 11%-51% B for 25 min, then 0 minutes at 100% B; flow rate: 20 mL / min; column temperature: 25 ° C. The collection of fractions was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 124 (42.6 mg, 0.084 mmol, 30% yield).
[0219] Example 3-Compound 121
[0220]
[0221]
[0222] Step 1. microwave bottle is loaded with 3-hydroxy-4-methylbenzoic acid methyl ester (2g, 12.04mmol), bromocyclopropane (1.747g, 14.44mmol), CsCO(4.71g, 14.44mmol) and DMF (15mL).In microwave oven, reaction mixture is heated at 160 ℃ for 3h.After cooling, reaction mixture is poured into water (150mL) and extracted with EtOAc (3x 50mL).The organic phase merged is washed with salt water (4x 50mL), dried (MgSO), filtered and concentrated.Flash chromatography (SiO2 column, 0 to 5% EtOAc hexane solution) obtains 3-cyclopropyloxy-4-methylbenzoic acid methyl ester (980mg, 1.901mmol, 15.79% yield, purity 40%) as oily matter, which is used for next step without further purification.
[0223] LC-MS (ES, m / z): [M+H] + 207.1.
[0224] Step 2. 3-cyclopropyloxy-4-methylbenzoic acid methyl ester (1g, 1.939mmol, 40% pure) is dissolved in CCl4 (5mL). NBS (0.759g, 4.27mmol) and benzoyl peroxide (0.103g, 0.427mmol) are added. The reaction mixture is stirred overnight at 70°C. After cooling, the reaction mixture is evaporated to dryness. Flash chromatography (SiO2 column, 0 to 10% EtOAc hexane solution) obtains 4-(bromomethyl)-3-cyclopropyloxybenzoic acid methyl ester (550mg, 1.54mmol, purity 80%, 80% yield) as solid. The product is used in the next step without further purification.
[0225] LC-MS (ES, m / z): [M+H] + 285.0,287.0.
[0226] Step 3. At 0 ° C, to a stirred solution of (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (650 mg, 1.894 mmol; US 2020 / 0038403 A1) in DMF (5 mL), Cs2CO3 (1296 mg, 3.98 mmol) was added, followed by a solution of 4-(bromomethyl)-3-cyclopropyloxybenzoic acid methyl ester (540 mg, 1.515 mmol, 80% pure) in DMF (2 mL). The reaction mixture was allowed to warm to room temperature, stirred overnight, poured into saturated NaHCO3 solution (100 mL), and extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with brine (4 x 50 mL), dried (MgSO4), filtered and concentrated. Flash chromatography (SiO column, 0 to 70% EtOAc in hexanes) afforded methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-cyclopropoxybenzoate (153 mg, 0.279 mmol, 14.76% yield) as an oil which solidified upon standing.
[0227] LC-MS (ES, m / z): [M+H] + 547.2,549.2.
[0228] 1 H NMR(400MHz,DMSO-d6)δ9.86(s,1H),7.80(d,J=1.5Hz,1H),7.53(dd,J=7.9,1.5Hz, 1H),7.32(t,J=5.5Hz,1H),6.91(d,J=7.9Hz,1H),5.72(s,2H),4.03-3.93(m,1H),3 .85(s,3H),3.71-3.60(m,3H),3.56-3.45(m,2H),1.56(quin,J=7.3Hz,2H),1.22(d q,J=14.8,7.4Hz,2H),0.85(t,J=7.4Hz,3H),0.81-0.73(m,2H),0.52-0.41(m,2H).
[0229] Step 4. Methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-cyclopropyloxybenzoate (150 mg, 0.274 mmol) was dissolved in EtOH (5 mL). 10% Pd / C (15 mg) was added. The reaction vessel was evacuated and purged with hydrogen six times. The reaction mixture was stirred for 1 h under a hydrogen atmosphere. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in dioxane (3 mL) and sodium hydroxide (822 μl, 4.11 mmol) was added. The reaction mixture was stirred at 80° C. for 2 h, cooled, acidified with 5N HCl, and diluted with water (5 mL). The organic solvent was evaporated and the aqueous residue was purified by reverse phase flash chromatography (C 18 Purification by ELISA® column, 0 to 70% MeCN in water with 0.05% TFA) gave 4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-cyclopropoxybenzoic acid (35 mg, 0.088 mmol, 32% yield) as a solid.
[0230] LC-MS (ES, m / z): [M+H] + 397.2.
[0231] 1 H NMR(400MHz,DMSO-d6)δ8.21(br t,J=5.6Hz,1H),7.81(br s,2H),7.73(s,1H),7.69(s,1H),7.42(dd,J=7.9,1.3Hz,1H),6.81(d,J=7.9Hz,1H),5.66(s,2H),3.87(tt,J=5.9,2.9Hz,1H),3.4 8(q,J=6.7Hz,2H),1.48(quin,J=7.3Hz,2H),1.14(sxt,J=7.4Hz,2H),0.78(t,J=7.4Hz,3H),0.75-0.68(m,2H),0.48-0.38(m,2H).
[0232] Step 5. A 20 mL scintillation vial was charged with 4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-cyclopropyloxybenzoic acid (35 mg, 0.088 mmol), HATU (40.3 mg, 0.106 mmol), 1-methylpiperidin-4-amine (20.16 mg, 0.177 mmol) and DMF (2 mL). DIPEA (0.046 mL, 0.265 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was filtered and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile:water (containing NH4OAc); Gradient: 2% B for 0 min, 2%-42% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 121 (31.2 mg, 0.063 mmol, 72% yield).
[0233] Compound 122 was prepared similarly.
[0234] Example 4-Compound 120
[0235]
[0236] Step 1. KOH (5N, 24.07mL, 120mmol) solution in water is added to the cooling (ice bath) solution of 3-hydroxy-4-methylbenzoic acid methyl ester (4g, 24.07mmol) in acetonitrile (150mL).After stirring for 5min at 0 ℃, (bromodifluoromethyl) diethyl phosphate (12.85g, 48.1mmol) is added. Allow the reaction mixture to be slowly heated to room temperature and stir for 16h. Add more KOH solution (5N, 16mL, 80mmol). The reaction mixture is stirred for 30min at room temperature, diluted with water (200mL), and extracted with EtOAc (3x 50mL). The organic phase merged is washed with salt water (2x 50mL), dried (MgSO4), filtered and concentrated. Flash chromatography (SiO2 column, 0 to 10% EtOAc in hexanes) afforded methyl 3-(difluoromethoxy)-4-methylbenzoate (2.552 g, 11.80 mmol, 49.0% yield) as an oil.
[0237] LC-MS (ES, m / z): [M+H] + 217.1.
[0238] 1 H NMR (400MHz, DMSO-d6) δ7.76 (dd, J = 7.8, 1.7Hz, 1H), 7.68 (br.s, 1H), 7.51-7.10 (m, 2H), 3.87 (s, 3H), 2.31 (s, 3H).
[0239] Step 2. NBS (1.811g, 10.18mmol) and benzoyl peroxide (0.448g, 1.850mmol) are added to the stirring solution of 3-(difluoromethoxy)-4-methylbenzoic acid methyl esters (2g, 9.25mmol) in carbon tetrachloride (20mL).The reaction is stirred for 4h at 75 ℃, then stirred at room temperature overnight.The reaction mixture is evaporated to dryness and flash chromatography (SiO2 post, 0 to 15% EtOAc hexane solution) is used to purify, so as to obtain 4-(bromomethyl)-3-(difluoromethoxy) methyl benzoate (1.561g, 5.29mmol, 57.2% yield) in oily matter.
[0240] LC-MS (ES, m / z): [M+H] + 295.0,297.0.
[0241] 1 H NMR (400MHz, CDCl3) δ7.88(dd,J=8.1,1.5Hz,1H),7.80(s,1H),7.52(d,J=8.1Hz,1H),6.64(t,J=73.0Hz,1H),4.57-4.51(m,2H),3.98-3.90(m,3H).
[0242] Step 3. CsCO (1329 mg, 4.08 mmol) is added to a stirred solution of (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methyl carbamate (700 mg, 2.040 mmol) in DMF (5 mL). After cooling in an ice bath, a solution of 4-(bromomethyl)-3-(difluoromethoxy)benzoic acid methyl ester (572 mg, 1.938 mmol) in DMF (2 mL) is added. The reaction mixture is allowed to warm to room temperature and stirred for 3 h. Water (20 mL) is added, and the reaction mixture is extracted with EtOAc (3 x 5 mL). The combined organic phases are washed with saline (4 x 10 mL), dried (MgSO), filtered and concentrated. Flash chromatography (SiO2 column, loaded in DCM, 0 to 60% EtOAc in hexanes) afforded methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-(difluoromethoxy)benzoate (275 mg, 0.493 mmol, 24.19% yield) as a solid.
[0243] LC-MS (ES, m / z): [M+H] + 557.1,559.1.
[0244] 1 H NMR (400MHz, DMSO-d6) δ9.89 (s, 1H), 7.82-7.69 (m, 2H), 7.61-7.14 (m, 2H), 6.87 (d, J = 7.9Hz, 1H), 5.88 (s, 2H), 3. 87(s,3H),3.64(s,3H),3.54-3.45(m,2H),1.58-1.46(m,2H),1.19(dq,J=15.0,7.4Hz,2H),0.83(t,J=7.3Hz,3H).
[0245] Step 4. Methyl 4-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-(difluoromethoxy)benzoate (275 mg, 0.493 mmol) was dissolved in EtOH (15 mL). 10% Pd / C (27 mg) was added. The reaction vessel was evacuated and purged with hydrogen six times, then stirred under a hydrogen atmosphere for 2 h. The reaction mixture was filtered and evaporated to dryness. The residue was dissolved in dioxane (2 mL). Sodium hydroxide (0.564 mL, 2.82 mmol) was added, and the reaction mixture was stirred at 80 °C for 2 h, then allowed to cool. The reaction mixture was neutralized with 5N HCl and evaporated to dryness. The residue was dissolved in MeOH / water (1:1, 8 mL). Methanol was removed by evaporation. The residual aqueous suspension was filtered (washing with water) to give 4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-(difluoromethoxy)benzoic acid (54 mg, 0.133 mmol, 27% yield) as a solid.
[0246] LC-MS (ES, m / z): [M+H] + =407.2.
[0247] 1 H NMR (400MHz, DMSO-d6) δ8.50 (br s, 1H), 7.84 (s, 2H), 7.79-7.68 (m, 2H), 7.63-7.05 (t, J=73.2Hz 1H), 6.97 (d, J = 7.9Hz, 1H), 5.94 (s, 2H), 3.54 (q, J = 6.4Hz, 2H), 1.54 (quin, J = 7.2Hz, 2H), 1.19 (dq, J = 14.9, 7.3Hz, 2H), 0.84 (t, J = 7.3Hz, 3H).
[0248] Step 5. A 20 mL scintillation vial was charged with 4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-(difluoromethoxy)benzoic acid (30 mg, 0.074 mmol), HATU (33.7 mg, 0.089 mmol), 2-(piperazin-1-yl)ethan-1-ol (9.61 mg, 0.074 mmol), and DMF (2 mL). DIPEA (0.039 mL, 0.221 mmol) was added. The reaction was stirred at room temperature for 1 h, filtered and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% TFA); Gradient: 0 min at 5% B, 5%-45% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give Compound 120 2TFA salt (28.1 mg, 0.037 mmol, 51% yield).
[0249] Example 5-Compound 117
[0250]
[0251] Step 1. A stirred solution of (7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methyl carbamate (4.98 g, 18.84 mmol; US 2020 / 0038403 A1) in DMF (60 mL) was cooled with an ice bath. NIS (5.09 g, 22.61 mmol) was added in batches. The reaction mixture was stirred at room temperature for 2 h and poured into water (400 mL). The product was collected by filtration to obtain (7-(butylamino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methyl carbamate (6.46 g, 15.73 mmol, 83% yield) as a solid.
[0252] LC-MS (ES, m / z): [M+H] + =391.1.
[0253] 'H NMR(400MHz,DMSO-d6)δ12.96(s,1H),9.74(s,1H),7.52(s,1H),3.62(s,3H), 3.53(q,J=6.5Hz,2H),1.68–1.55(m,2H),1.40(m,2H),0.94(t,J=7.4Hz,3H).
[0254] Step 2. CsCO (4.18 g, 12.81 mmol) was added to a stirred solution of methyl (7-(butylamino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.5 g, 6.41 mmol) in DMF (50 mL). After sonication for 5 min, a solution of methyl 4-(bromomethyl)-3-methoxybenzoate (1.743 g, 6.73 mmol) in DMF (10 mL) was added. The reaction mixture was stirred at room temperature for 2 h, poured into 10% citric acid solution (100 mL), and extracted with DCM (3 x 100 mL). The combined organic phases were washed with brine, dried (NaSO), filtered and concentrated. Flash chromatography (SiO column, 0 to 100% EtOAc in hexanes) afforded methyl 4-((7-(butylamino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (2.26 g, 2.98 mmol, 46% yield, 75% purity) as a solid which was used in the next step without further purification.
[0255] LC-MS (ES, m / z): [M+H] + =569.2.
[0256] Step 3. A 20 mL microwave vial was charged with methyl 4-((7-(butylamino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (1.34 g, 1.771 mmol, 75% purity), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl, 91 mg, 0.124 mmol), trimethylboroxine (TMB, 1001 mg, 7.97 mmol), KCO (734 mg, 5.31 mmol) and dioxane (7 mL). The reaction mixture was heated at 120°C in a microwave oven for 1 h and diluted with DCM and 10% citric acid. The phases were separated. The organic phase was washed sequentially with 10% citric acid and brine, dried (NaSO), filtered and concentrated under reduced pressure. Flash chromatography afforded methyl 4-((5-amino-7-(butylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (422 mg, 1.06 mmol, 59.8 % yield) as a solid.
[0257] LC-MS (ES, m / z): [M+H] + =399.2.
[0258] Step 4. NaOH (1.190 mL, 5.95 mmol) was added to a suspension of methyl 4-((5-amino-7-(butylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (237 mg, 0.595 mmol) in dioxane (5 mL). The reaction mixture was stirred at 80 °C for 1 h, cooled, neutralized with 5N hydrochloric acid, and evaporated to dryness. The residue was suspended in DMSO (2 mL) and water (20 mL) and filtered off (washed with water) to give 4-((5-amino-7-(butylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (184 mg, 0.479 mmol, 80% yield) as a solid.
[0259] LC-MS(ES,m / z):[MH] + =383.2.
[0260] Step 5. A 20 mL scintillation vial was charged with 4-((5-amino-7-(butylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (35 mg, 0.091 mmol), HBTU (41.4 mg, 0.109 mmol), 1-methylpiperidin-4-amine (20.79 mg, 0.182 mmol) and DMF (2 mL). DIPEA (0.048 mL, 0.273 mmol) was added. The reaction was stirred at room temperature overnight. The reaction mixture was filtered and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); Gradient: 0 min at 3% B, 3%-43% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 117 (37.6 mg, 0.78 mmol, 85%).
[0261] Compound 118 and Compound 119 were prepared similarly.
[0262] Example 6-Compound 126 TFA Salt
[0263]
[0264] Step 1: NaOH (651 mg, 16.26 mmol) was added to a suspension of methyl 3-methoxy-4-((5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)benzoate (630 mg, 1.626 mmol; US2020 / 0038403 A1) in dioxane (16 mL) and water (3.3 mL). The reaction mixture was heated at 80 °C for 2 h and cooled. The dioxane was evaporated. The reaction mixture was diluted with water and acidified to pH 4 with concentrated HCl. The precipitate was filtered off, washed with water, and dried. The material was azeotroped with toluene and further dried to give 4-((5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (500 mg, 1.586 mmol, 98% yield).
[0265] LC / MS (Method F): RT = 0.50 min. M / Z = 316.0.
[0266] Step 2: Hunig's base (0.277 mL, 1.586 mmol) and HATU (332 mg, 0.872 mmol) were added to a suspension of 1-methylpiperidin-4-amine (136 mg, 1.189 mmol) and 4-((5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (250 mg, 0.793 mmol) in DMF (5 mL). The reaction mixture was heated to 50° C. After 4.5 h, 1-methylpiperidin-4-amine (136 mg, 1.189 mmol) and 160 mg HATU were added and the reaction mixture was heated overnight. 200 mg of piperidine, HATU (332 mg, 0.872 mmol) and Hunin's base (0.277 mL, 1.586 mmol) were added and heating was continued for 5 h. 1-Methylpiperidin-4-amine (136 mg, 1.189 mmol) and HATU (332 mg, 0.872 mmol) were added and heating was continued overnight. 1-Methylpiperidin-4-amine (136 mg, 1.189 mmol) and 165 mg of HATU were added. After 5 h, the reaction mixture was cooled and diluted with water. The solid was collected by filtration, washed with water, and dried to give 4-((5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (126 mg, 0.306 mmol, 38.6% yield).
[0267] 1H NMR (400MHz, DMSO-d6) δ8.16(d,J=7.6Hz,1H),7.57(s,1H),7.41(d,J=1.3Hz,1H),7.32-7.26(m,1H),6.52(d,J=8.0Hz,1H),6.05(br d,J=1.8Hz,2H),5.63(s,2H),3.88(s,3H),3.74-3.63(m,1H),2.80-2.71(m ,2H),2.15(s,3H),1.97-1.86(m,2H),1.79-1.68(m,2H),1.62-1.49(m,2H).
[0268] LC / MS (Method A): RT = 0.52 min. M / Z = 412.4.
[0269] Step 3. DBU (0.022 mL, 0.146 mmol) and BOP (48.4 mg, 0.109 mmol) were added to a suspension of (S)-2-aminopentan-1-ol (37.6 mg, 0.365 mmol) and 4-((5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (30 mg, 0.073 mmol) in DMF (0.5 mL). All suspended material dissolved within minutes. After 1.75 h, the reaction mixture was cooled, diluted with MeOH, and filtered through a syringe filter. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% TFA); Gradient: 0 min at 5% B, 5%-45% B over 25 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford compound 126 (16 mg, 0.025 mmol, 34.2% yield) as its TFA salt.
[0270] Example 7-Compound 123
[0271]
[0272] Step 1. DBU (0.856 mL, 5.68 mmol) was added to a suspension of methyl 4-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (550 mg, 1.420 mmol; see step 6 of Example 2 before NaOH treatment) and (S)-3-aminohexan-1-ol hydrochloride 2 (327 mg, 2.130 mmol) in DMSO (5 mL). The reaction mixture was stirred at room temperature for 10 min, at which time it became a clear solution. BOP (1256 mg, 2.84 mmol) was added. The reaction mixture was stirred at 70° C. for 2 h. 5 M NaOH (5 mL, 25.00 mmol) was added, and the reaction mixture was stirred at 70° C. for 0.5 h. After cooling, it was filtered through a syringe filter disk. The filtrate was purified on a preparative reverse phase C18 column (150 g) eluting with a 0-50% gradient of acetonitrile:water (with 0.05% TFA modifier). The desired fractions were frozen and lyophilized to provide (S)-4-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (860.8 mg, 1.246 mmol, 88% yield).
[0273] LCMS ESI: for C 20 H 27 Calculated value for N6O4 = 415.2 (M+H + ), found value 415.2 (M+H + ).
[0274] Step 2. A mixture of (S)-4-((5-amino-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (30 mg, 0.072 mmol), 2-(piperazin-1-yl)ethan-1-ol (18.85 mg, 0.145 mmol) in DMF (1 mL) was treated with Hunin's base (0.063 mL, 0.362 mmol) followed by BOP (48.0 mg, 0.109 mmol). The reaction mixture was stirred at room temperature for 3 h and filtered through a syringe frit. The filtrate was purified via LC / MS method H. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound 123 (12.1 mg, 0.022 mmol, 30.1% yield).
[0275] Compound 125 was prepared similarly.
[0276] Example 8-Compound 101
[0277]
[0278] Step 1. A solution of (S)-methyl 4-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (30 mg, 0.041 mmol; US 2020 / 0038403 A1) in dioxane (1 mL) was treated with NaOH (0.207 mL, 0.207 mmol) and heated at 80 °C for 2 h. The reaction mixture was neutralized to pH 7 by slow addition of 6M aqueous HCl. The solvent was evaporated in a V-10 apparatus and the residue was dissolved in DMF (2 mL) and filtered. The filtrate was purified on a reverse phase ISCO (50 g column) (eluting with 0-50% acetonitrile / water 90.05%) formic acid. The product containing fractions were lyophilized to afford the desired product as a white solid. LCMS ESI: for C 36 H 44 Calculated value for N6O4Si = 653.8 (M+H + ), found value 653.4 (M+H + ).
[0279] Step 2. A solution of (S)-4-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (26 mg, 0.040 mmol) in DMF (1 mL) was treated with HATU (22.71 mg, 0.060 mmol) and stirred for 10 min before adding piperidin-4-ylmethanamine (4.55 mg, 0.040 mmol). After 30 min, LCMS (M+H=749.6) showed the reaction was complete. The solution was treated with triethylamine trihydrofluoride (0.065 mL, 0.398 mmol) and stirred for 2 h after which LCMS (M+H=511.3) showed loss of the TBDPS protecting group. Excess triethylamine trihydrofluoride (0.065 mL, 0.398 mmol) was neutralized by saturated aqueous NaHCO solution (1 mL), and the solvent was evaporated in a V-10 apparatus. The crude material was purified via LC / MS method I. The fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 101 (6.7 mg, 32% yield).
[0280] Example 9-Compound 127
[0281]
[0282] Step 1: A solution of methyl 4-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (US 2020 / 0038403 A1; 300 mg, 0.774 mmol) in DMSO (3.9 mL) was treated with (5-methylisoxazol-3-yl)methanamine (174 mg, 1.55 mmol), BOP (411 mg, 0.929 mmol) and DBU (233 μl, 1.549 mmol). The reaction mixture was stirred at room temperature for 2 h, diluted with EtOAc and washed with H2O (3x). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give methyl 3-methoxy-4-((5-((methoxycarbonyl)amino)-7-(((5-methylisoxazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)benzoate (353 mg, 95% yield).
[0283] 1 H NMR(400MHz, DMSO-d6)δ9.80(s,1H),7.99-7.93(m,1H),7.77(t,J=5.9Hz,1H),7.49(d,J=1.5Hz,1H),7.45(dd,J=7.8,1.5Hz,1H),6 .62(d,J=7.9Hz,1H),6.10(d,J=0.9Hz,1H),5.80(s,2H),4.73(d,J=5.9Hz,2H),3.84(s,3H),3.82(s,3H),3.64(s,3H),2.31(s,3H).
[0284] LC RT: 0.67 min. LC / MS [M+H] + 482.3 (Method J)
[0285] Step 2. A solution of methyl 3-methoxy-4-((5-((methoxycarbonyl)amino)-7-(((5-methylisoxazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)benzoate (125 mg, 0.260 mmol) in dioxane (1.3 mL) was treated with NaOH (10 M aqueous solution, 0.2 mL, 2.0 mmol) and heated to 75° C. After 2 h, the reaction mixture was cooled to room temperature and treated with HCl (4 M in dioxane, 0.52 mL, 2.1 mmol) and concentrated in vacuo. The residue was redissolved in MeOH / DCM and concentrated in vacuo. 40mg of this crude material is dissolved in DMF (469 μl) and treated with 2-(piperazine-1-yl) ethane-1-ol (12mg, 0.094mmol), DIEA (41 μl, 0.23mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (50% EtOAc solution, 55.8 μL, 0.094mmol). The reaction mixture is stirred at room temperature for 1h, diluted with DMF (1mL) and H2O (0.2mL), and filtered through a PTFE glass frit. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% TFA); Gradient: 0 min at 0% B, 0-30% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing product were combined and dried via centrifugal evaporation to give compound 127 as a bis-TFA salt. (11.7 mg, 39% yield).
[0286] Compound 129, Compound 130 and Compound 131 were prepared similarly.
[0287] Example 10-Compound 128
[0288]
[0289] Step 1. Mix methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1 g, 4.78 mmol) and Selectfluor TMThe fluoro-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidine-5-yl)carbamate (623mg, 2.74mmol, 57.4% yield) of 3-fluoro-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidine-5-yl)carbamate was added to the mixture.Then the fluoro-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidine-5-yl)carbamate (5.08g, 14.34mmol) was suspended in acetonitrile (20mL).Acetic acid (2mL) was added.The reaction mixture was stirred at 70 °C for 24h, cooled, and poured into water (100mL).The resulting mixture was cooled in a refrigerator (-20 °C) for 30min, then the product was filtered out (washed with water (40mL)), so as to obtain (3-fluoro-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidine-5-yl)carbamate (623mg, 2.74mmol, 57.4% yield) as a solid.
[0290] LC-MS (ES, m / z): [M+H] + =228.2.
[0291] 1 H NMR (400MHz, DMSO-d6) δ13.69(s,1H),11.63(s,1H),11.26(s,1H),3.76(s,3H).
[0292] Step 2. by (3-fluoro-7-hydroxyl-1H-pyrazolo [4,3-d] pyrimidine-5-yl) methyl carbamate (620mg, 2.73mmol) and CsCO(1030mg, 3.16mmol) stirred suspension in DMF (5mL) is cooled in ice bath.Add solution of 4-(bromomethyl)-3-methoxybenzoic acid methyl ester (744mg, 2.87mmol) in DMF (5mL).Allow reaction to be slowly heated to room temperature, stir 2h, pour in water (100mL), and extract with EtOAc (3x 100mL).By the organic phase merged salt water (4x 50mL) washing, dry (MgSO), filter and concentrate. Flash chromatography (40 g SiO2 column supported on silica, 0 to 100% EtOAc in hexanes) afforded methyl 4-((3-fluoro-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (342 mg, ca. 60% pure, 0.506 mmol, 17.6% yield) as a solid.
[0293] LC-MS (ES, m / z): [M+H] + =406.2.
[0294] Step 3. A 20 mL scintillation vial was charged with methyl 4-((3-fluoro-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (340 mg, 0.839 mmol), (S)-3-aminohexan-1-ol HCl (193 mg, 1.258 mmol), BOP (742 mg, 1.678 mmol), DMSO (4 mL) and DBU (0.379 mL, 2.52 mmol). The reaction mixture was heated at 70 °C for 15 min, cooled, poured into saturated NaHCO3 solution (100 mL), and extracted with EtOAc (3x40 mL). The combined organic phases were washed with brine (4x 40 mL), dried (MgSO4), filtered and concentrated. Flash chromatography (40 g SiO column, 0 to 100% EtOAc in hexanes) afforded (S)-methyl 4-((3-fluoro-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (105 mg, 0.208 mmol, 24.8% yield) as a solid.
[0295] LC-MS (ES, m / z): [M+H] + =505.3.
[0296] 1 H NMR (400MHz, DMSO-d6) δ9.90 (s, 1H), 7.52 (s, 1H), 7.49 (d, J = 8.2Hz, 1H), 6.74 (d, J = 7. 7Hz,1H),6.69(d,J=7.9Hz,1H),5.77(d,J=17.2Hz,1H),5.61(d,J=16.9Hz,1H),4.54-4 .43(m,1H),4.38(t,J=5.5Hz,1H),3.87(s,3H),3.85(s,3H),3.63(s,3H),3.45-3.34( m,2H),1.75-1.62(m,2H),1.58-1.40(m,2H),1.18-1.01(m,2H),0.75(t,J=7.4Hz,3H).
[0297] Step 4. (S)-methyl 4-((3-fluoro-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (100 mg, 0.198 mmol) was dissolved in dioxane (2 mL) and sodium hydroxide (0.595 mL, 2.97 mmol) was added. The reaction mixture was stirred at 80° C. for 2 hours and then at room temperature overnight. The reaction mixture was neutralized with 5N HCl and evaporated to dryness to give (S)-4-((5-amino-3-fluoro-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (210 mg, -40% pure, 0.19 mmol, 98% yield) which was then used without purification.
[0298] LC-MS (ES, m / z): [M+H] + =433.2.
[0299] Step 5. A 20 mL scintillation vial was charged with (S)-4-((5-amino-3-fluoro-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid (70 mg, 0.081 mmol), HATU (36.9 mg, 0.097 mmol) and DMF (2 mL). 1-Methylpiperidin-4-amine (18.48 mg, 0.162 mmol) was added followed by DIPEA (0.042 mL, 0.243 mmol). The reaction mixture was stirred at room temperature for 1 h, filtered, and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile:water (containing NH4OAc); Gradient: 0 min at 4% B, 4%-44% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 128 (15.1 mg, 0.028 mmol, 34.7% yield).
[0300] Example 11-Compound 132
[0301]
[0302] Step 1. A solution of methyl 4-((7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoate (510 mg, 1.32 mmol; US 2020 / 0038403 A1, Figure 2A, compound 16) in DMSO (6.6 mL) was treated with (5-methyl-1,2,4-oxadiazol-3-yl)methanamine HCl (236 mg, 1.58 mmol), BOP (698 mg, 1.58 mmol) and DBU (595 μL, 3.95 mmol). The reaction was stirred at room temperature. After 16 h, additional (5-methyl-1,2,4-oxadiazol-3-yl)methanamine HCl (50 mg, 0.33 mmol), BOP (50 mg, 0.11 mmol), and DBU (200 μL, 1.33 mmol) were added. The reaction was stirred at room temperature for 2 h, diluted with EtOAc, and washed with H2O (4x). The organic layer was adsorbed onto celite and purified via column chromatography (100 g C18 gold column; mobile phase A: 5:95 acetonitrile:water (with 0.05% trifluoroacetic acid); mobile phase B: 95:5 acetonitrile:water (with 0.05% trifluoroacetic acid); flow rate: 60 mL / min, 20%-60% gradient). Fractions containing the desired product were combined, treated with HCl (1 M in H2O, 2 mL, 2 mmol) and concentrated in vacuo to give methyl 3-methoxy-4-((5-((methoxycarbonyl)amino)-7-(((5-methyl-1,2,4-oxadiazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)benzoate (382 mg, 60% yield). 1 H NMR (400MHz, DMSO-d6) δ9.72-9.70(m,1H),7.96-7.94(m,1H),7.83-7.76(m,1H),7.49(d,J=1.4Hz,1H),7.46(dd,J=7.8,1 .5Hz,1H),6.74(d,J=7.8Hz,1H),5.79(s,2H),4.86(d,J=5.8Hz,2H),3.86(s,3H),3.84(s,3H),3.60(s,3H),2.54(s,3H). LC RT: 0.64min. LC / MS[M+H] + 483.3 (Method J).
[0303] Step 2. A solution of methyl 3-methoxy-4-((5-((methoxycarbonyl)amino)-7-(((5-methyl-1,2,4-oxadiazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)benzoate (382 mg, 0.791 mmol) in dioxane (9.0 mL) was treated with NaOH (10 M aqueous solution, 0.32 mL, 3.2 mmol) and heated to 40° C. After 30 minutes, the temperature was increased to 60° C. Additional portions of NaOH (10 M aqueous solution, 450 μL, 3 mmol) and MeOH (1 mL) were added to the reaction mixture over a period of 6 h. The reaction mixture was cooled to room temperature, neutralized with HOAc and concentrated in vacuo. The crude product was dissolved in MeOH, filtered through a PTFE frit, and purified via preparative HPLC with the following conditions: Column: Axia C18 100 mm x 30 mm, 5 μm particles; Mobile phase A: 10:90 methanol:water (with 0.1% trifluoroacetic acid); Mobile phase B: 90:10 methanol:water (with 0.1% trifluoroacetic acid); Gradient: 15% B for 0 min, 15%-30% B over 10 min, then 30% B for 4 min; Flow rate: 40 mL / min; UV detection at 220 nm; Column temperature: 25°C. Fractions containing the desired product were combined, treated with HCl (1 M in H2O, 2 mL, 2 mmol) and concentrated in vacuo to give 4-((5-amino-7-(((5-methyl-1,2,4-oxadiazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid HCl (98.9 mg, 28% yield). 1 H NMR (400MHz, DMSO-d6) δ13.23-12.93(m,1H),12.67-12.43(m,1H),9.06-8.92(m,1H),8.03-7.87(m,2H),7.83( s,1H),7.51-7.46(m,2H),6.98(d,J=8.2Hz,1H),5.80(s,2H),4.91(d,J=5.7Hz,2H),3.82(s,3H),2.57(s,3H). LCRT: 0.52min. LC / MS[M+H] + 411.3 (Method J).
[0304] Step 3. A solution of 4-((5-amino-7-(((5-methyl-1,2,4-oxadiazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxybenzoic acid HCl (25 mg, 0.056 mmol) in DMF (0.6 mL) was treated with 1-methylpiperazine (11.2 mg, 0.112 mmol), DIEA (49 μL, 0.28 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide (50% in EtOAc, 67 μL, 0.11 mmol). The reaction mixture was stirred at room temperature for 16 h and treated with additional 1-methylpiperazine (11.2 mg, 0.112 mmol), DIEA (49 μL, 0.28 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide (50% solution in EtOAc, 67 μL, 0.11 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with DMF (1 mL) and H2O (0.2 mL) and filtered through a PTFE frit. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 10 mM NH4OAc); Mobile phase B: 95:5 acetonitrile:water (containing 10 mM NH4OAc); Gradient: 0 min at 0% B, 0-40% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound 132 (16.6 mg, 59% yield).
[0305] Compound 133 was prepared similarly.
[0306] Example 12 - Starting Materials and Intermediates
[0307] The scheme below shows a scheme for preparing compounds that can be used as starting materials or intermediates for preparing TLR7 agonists disclosed herein. The scheme can be applied to prepare other similar compounds that can be used as starting materials or intermediates. The reagents used are well known in the art, and in many cases, their use has been demonstrated in the aforementioned examples.
[0308] Solution 5
[0309]
[0310] Solution 6
[0311]
[0312]
[0313] Biological Activity
[0314] The biological activity of the compounds disclosed herein as TLR7 agonists can be determined by the following procedure.
[0315] Human TLR7 agonist activity assay
[0316] This procedure describes a method for determining the human TLR7 (hTLR7) agonist activity of compounds disclosed in this specification.
[0317] Human embryonic kidney blue cells (HEK-Blue) with a human TLR7 secretory embryonic alkaline phosphatase (SEAP) reporter transgene were engineered to express TM HEK-Blue TLR cells (Invivogen) were suspended in non-selective medium (DMEM high glucose (Invitrogen) supplemented with 10% fetal bovine serum (Sigma). TM TLR7 cells were added to each well of a 384-well tissue culture plate (15,000 cells / well) and incubated at 37°C, 5% CO2 for 16-18 h. Compounds (100 nl) were dispensed into the HEK-Blue TM TLR cells were added to the wells and the treated wells were incubated at 37°C, 5% CO2. After 18 h of treatment, ten microliters of freshly prepared Quanti-Blue TM The reagent (Invivogen) was added to each well, incubated for 30 min (37°C, 5% CO2), and the SEAP level was measured using an Envision plate reader (OD = 620 nm). The half-maximal effective concentration (EC 50 ; the concentration of compound that elicits a response halfway between the assay baseline and maximum).
[0318] Induction of type I interferon gene (MX-1) and CD69 in human blood
[0319] Induction of the type I interferon (IFN) MX-1 gene and the B cell activation marker CD69 are downstream events that occur following activation of the TLR7 pathway. The following is a human whole blood assay that measures induction in response to a TLR7 agonist.
[0320] Heparinized human whole blood was harvested from human subjects and treated with 1mM of the test TLR7 agonist compound. Blood was diluted with RPMI 1640 culture medium and 10nL / well was pre-dotted using Echo to obtain a final concentration of 1uM (10nL in 10uL blood). After mixing on a shaker for 30 seconds, the plate was covered and placed in a 37°C chamber overnight = 17h. Fixation / lysis buffer (5x->1x in H2O, heated at 37°C; Catalog No. BD 558049) was prepared and perm buffer (on ice) was kept for later use.
[0321] For surface marker (CD69) staining: Prepare surface Ab: 0.045ul hCD14-FITC (ThermoFisher catalog number MHCD1401) + 0.6ul hCD19-ef450 (ThermoFisher catalog number 48-0198-42) + 1.5ul hCD69-PE (catalog number BD555531) + 0.855ul FACS buffer. Add 3ul / well, rotate 1000rpm for 1min, and mix on a shaker for 30 seconds, place on ice for 30min. Stop stimulation after 30min with 70uL pre-warmed 1x fixation / lysis buffer, and resuspend using Feliex partner (15 times, change the tip for each plate) and incubate at 37C for 10min.
[0322] Centrifuge at 2000rpm for 5min, draw off with HCS plate washer, mix on shaker for 30 seconds, then wash and pellet 2 times with 70uL in dPBS (2000rpm for 5min), and wash and pellet 1 time with 50ul in FACS buffer (2000rpm for 5min). Mix on shaker for 30 seconds. For intracellular marker (MX-1) staining: add 50ul BDPerm buffer III and mix on shaker for 30 seconds. Incubate on ice for 30 minutes (in the dark). Wash 2 times with 50uL FACS buffer (spin at 2300rpm for 5min after perm), then mix on shaker for 30 seconds. Resuspend in 20ul FACS buffer containing MX1 antibody ((4812)-Alexa 647: Novus Biologicals #NBP2-43704AF647) 20ul FACS buffer + 0.8ul hIgG + 0.04ul MX-1. Spin at 1000rpm for 1min, mix on a shaker for 30 seconds, and incubate the sample in the dark at room temperature for 45 minutes, then wash twice with FACS buffer (after perm, spin at 2300rpm for 5min). Resuspend in 20ul (35uL total per well) FACS buffer, and cover with foil and place at 4°C to read the next day. Read the plate on iQuePlus. Load the results into the tool set and generate an IC50 curve in curve master. Set the y-axis 100% to 1uM resiquimod.
[0323] Induction of TNF-α and type I IFN-responsive genes in mouse blood
[0324] Induction of TNF-α and type I IFN response genes are downstream events that occur following activation of the TLR7 pathway. The following is an assay to measure induction in response to TLR7 agonists in mouse whole blood.
[0325] Heparinized mouse whole blood was diluted with RPMI 1640 culture medium containing penicillin-streptomycin at a ratio of 5:4 (50uL whole blood and 40uL culture medium). 90uL volume of diluted blood was transferred to the wells of Falcon flat-bottom 96-well tissue culture plates, and the plate was incubated for 1h at 4°C. The test compound in 100% DMSO stock solution was diluted 20 times in the same culture medium for concentration response determination, and then 10uL diluted test compound was added to the wells so that the final DMSO concentration was 0.5%. Control wells received 10uL culture medium containing 5% DMSO. The plate was then incubated for 17h at 37°C in a 5% CO2 incubator. After incubation, 100uL culture medium was added to each well. The plate was centrifuged, and 130uL supernatant was taken out for measuring the generation of TNFa by ELISA (Invitrogen, catalog number 88-7324, Thermo-Fisher Scientific). 70uL volume of mRNA capture lysis buffer (1x) containing DTT from Invitrogen mRNA Catcher Plus kit (Catalog No. K1570-02) was added to the remaining 70uL sample in the well and mixed by pipetting up and down 5 times. The plate was then shaken at room temperature for 5-10min, and then 2uL proteinase K (20mg / mL) was added to each well. The plate was then shaken at room temperature for 15-20min. The plate was then stored at -80°C until further processing.
[0326] Frozen samples were thawed and mRNA was extracted using the Invitrogen mRNA CatcherPlus kit (Cat. No. K1570-02) according to the manufacturer's instructions. Half of the mRNA yield from RNA extraction was used to synthesize cDNA in a 20 μL reverse transcriptase reaction using Invitrogen SuperScript IV VILO MasterMix (Cat. No. 11756500). QuantStudio Real-Time PCR System from ThermoFisher (Applied Biosystems) was used for Real-time PCR. All real-time PCR reactions were run in duplicate using commercial pre-designed TaqMan assays and TaqMan Master Mix for mouse IFIT1, IFIT3, MX1 and PPIA gene expression. PPIA was used as a housekeeping gene. The advice from the manufacturer was followed. All raw data (Ct) were normalized by the average housekeeping gene (Ct), and then the relative gene expression (RQ) was quantified using the comparative Ct (ΔΔCt) method for experimental analysis.
[0327] definition
[0328] "Aliphatic" means a straight or branched chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having a specified number of carbon atoms (e.g., as in "C3 aliphatic," "C 1-5 In the phrases "aliphatic", "C1-C5 aliphatic" or "C1 to C5 aliphatic", the latter three phrases are synonymous with aliphatic moieties having from 1 to 5 carbon atoms) or, if the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the case of unsaturated aliphatic moieties). A similar understanding applies to the number of carbons in the other types, such as in C 2-4 olefins, C4-C7 alicyclics, etc. In a similar manner, such as "(CH2) 1-3 " are to be understood as shorthand for subscripts 1, 2, or 3, such that such terms represent CH2, CH2CH2, and CH2CH2CH2.
[0329] "Alkyl" means a saturated aliphatic moiety in which the same conventions for specifying the number of carbon atoms are applicable. By way of illustration, C1-C4 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, 1-butyl, 2-butyl, and the like. "Alkanediyl" (sometimes also referred to as "alkylene") means the divalent counterpart of an alkyl group, such as
[0330]
[0331] "Alkenyl" means an aliphatic moiety having at least one carbon-carbon double bond, wherein the same convention for specifying the number of carbon atoms is applicable. By way of illustration, C2-C4 alkenyl moieties include, but are not limited to, ethenyl / vinyl, 2-propenyl (allyl or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E- (or Z-) 2-butenyl, 3-butenyl, 1,3-butadienyl (buta-1,3-dienyl), and the like.
[0332] "Alkynyl" means an aliphatic moiety having at least one carbon-carbon triple bond, wherein the same convention for specifying the number of carbon atoms is applicable. By way of illustration, C2-C4 alkynyl includes ethynyl (ethynyl / acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, etc.
[0333] "Alicyclic" means a saturated or unsaturated non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms. "Cycloalkyl" means an alicyclic moiety in which each ring is saturated. "Cycloalkenyl" means an alicyclic moiety in which at least one ring has at least one carbon-carbon double bond. "Cycloalkynyl" means an alicyclic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, alicyclic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl and adamantyl. Preferred alicyclic moieties are cycloalkyl moieties, especially cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. "Cycloalkanediyl" (sometimes also referred to as "cycloalkylene") means the divalent counterpart of cycloalkyl. Similarly, "bicycloalkanediyl" (or "bicycloalkylene") and "spiroalkanediyl" (or "spiroalkylene") refer to the divalent counterparts of bicycloalkyl and spiroalkyl (or "spirocycloalkyl").
[0334] "Heteroalicyclic" means an alicyclic moiety in which, in at least one of its rings, up to three (preferably 1 to 2) carbons have been replaced by heteroatoms independently selected from N, O or S, wherein N and S may optionally be oxidized and N may optionally be quaternized. Preferred alicyclic moieties consist of a ring size of 5 to 6 members. Similarly, "heterocycloalkyl", "heterocycloalkenyl" and "heterocycloalkynyl" mean a cycloalkyl, cycloalkenyl or cycloalkynyl moiety, respectively, in which at least one ring has been so modified. Exemplary heteroalicyclic moieties include aziridine, azetidinyl, 1,3-dioxanyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothiphenyl, 1,4-dioxanyl, thietanyl, and the like. "Heterocycloalkylene" means the divalent counterpart of heterocycloalkyl.
[0335] "Alkoxy", "aryloxy", "alkylthio" and "arylthio" mean -O(alkyl), -O(aryl), -S(alkyl) and -S(aryl), respectively. Examples are methoxy, phenoxy, methylthio and phenylthio, respectively.
[0336] Unless a narrower meaning is indicated, "halogen" or "halo" means fluorine, chlorine, bromine or iodine.
[0337] "Aryl" means a hydrocarbon moiety having a mono-, bi- or tricyclic ring system (preferably monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl), and may be fused to or bonded to a non-aromatic ring (as in indanyl or cyclohexylphenyl). By way of further illustration, aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthrenyl, anthracenyl, and acenaphthenyl. "Arylene" means the divalent counterpart of aryl, such as 1,2-phenylene, 1,3-phenylene or 1,4-phenylene.
[0338] "Heteroaryl" means a moiety having a mono-, bi- or tricyclic ring system (preferably a 5- to 7-membered monocyclic ring), wherein each ring has from 3 to 7 carbon atoms, and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from N, O or S, wherein N and S may optionally be oxidized and N may optionally be quaternized. Such at least one aromatic ring containing heteroatoms may be fused to other types of rings (such as in benzofuranyl or tetrahydroisoquinolinyl), or directly bonded to other types of rings (such as in phenylpyridinyl or 2-cyclopentylpyridinyl). By way of further illustration, heteroaryl moieties include pyrrolyl, furanyl, thiophenyl / thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridinyl, N-oxopyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolynyl, quinazolinyl, cinnolinyl, quinozalinyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl, acridinyl, and the like. "Heteroarylene" means the divalent counterpart of a heteroaryl.
[0339] Where a moiety is indicated to be substituted (such as by using the phrase "unsubstituted or substituted" or "optionally substituted" as in "unsubstituted or substituted C1-C5 alkyl" or "optionally substituted heteroaryl"), such a moiety may have one or more independently selected substituents, preferably in an amount of 1 to 5, more preferably in an amount of 1 or 2. Substituents and substitution patterns can be selected by one of ordinary skill in the art, taking into account the moiety to which the substituents are attached, to provide a compound that is chemically stable and that can be synthesized by techniques known in the art and the methods outlined herein. Where a moiety is identified as "unsubstituted or substituted" or "optionally substituted", in a preferred embodiment, such a moiety is unsubstituted.
[0340] "Arylalkyl", "(heteroalicyclic)alkyl", "arylalkenyl", "arylalkynyl", "biarylalkyl" and the like mean alkyl, alkenyl or alkynyl moieties (as the case may be) substituted with aryl, heteroalicyclic, biaryl, etc. moieties (as the case may be) with the open (unsatisfied) valences being at the alkyl, alkenyl or alkynyl moiety, e.g., as in benzyl, phenethyl, N-imidazolylethyl, N-morpholinoethyl, etc. Conversely, "alkylaryl", "alkenylcycloalkyl" and the like mean aryl, cycloalkyl, etc. moieties (as the case may be) substituted with alkyl, alkenyl, etc. moieties (as the case may be) such as in methylphenyl (tolyl) or allylcyclohexyl. "Hydroxyalkyl", "haloalkyl", "alkylaryl", "cyanoaryl" and the like mean alkyl, aryl, etc. moieties (as the case may be) substituted with one or more identified substituents (hydroxy, halo, etc., as the case may be).
[0341] For example, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, alicyclic, heteroalicyclic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxy, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl) (especially -OCF3), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -C(=O)(alkyl), -C(=O)H, -C02H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl), -OCF3, -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -NH(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), -SO2N(alkyl)2, etc.
[0342] In the case where the substituted moiety is an aliphatic moiety, preferred substituents are aryl, heteroaryl, alicyclic, heteroalicyclic, halo, hydroxy, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl), -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC( -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(=O)alkyl, -S(cycloalkyl), -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), and -SO2N(alkyl)2. More preferred substituents are halo, hydroxy, cyano, nitro, alkoxy, -O(aryl), =O, =NOH, =NO(alkyl), -OC(=O)(alkyl), -OC(=O)O(alkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl), azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl), and -NHC(=NH)NH2. Particularly preferred are phenyl, cyano, halo, hydroxy, nitro, C1-C4 alkoxy, O(C2-C4 alkanediyl)OH, and O(C2-C4 alkanediyl)halo.
[0343] In the case where the substituted moiety is an alicyclic, heteroalicyclic, aryl or heteroaryl moiety, preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(aryl), -O(cycloalkyl), -O(heterocycloalkyl), alkylthio, arylthio, -C(=O)(alkyl), -C(=O)H, -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), and -SO2N(alkyl)2. More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -C(=O)(alkyl), -C(=O)H, -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2 and -NHC(=NH)NH2. Particularly preferred are C1-C4 alkyl, cyano, nitro, halo and C1-C4 alkoxy.
[0344] Where a range is stated, such as in "C1-C5 alkyl" or "5% to 10%", such a range includes the endpoints of the range, such as C1 and C5 in the first example and 5% and 10% in the second example.
[0345] Unless a particular stereoisomer is specifically indicated (e.g., by bolding or dashing bonds at the relevant stereocenter in a structural formula, by depicting double bonds in a structural formula as having the E or Z configuration, or by using stereochemically designated nomenclature or symbols), all stereoisomers as pure compounds and mixtures thereof are included within the scope of the present invention. Unless otherwise indicated, racemates, individual enantiomers (whether optically pure or partially resolved), diastereomers, geometric isomers, and combinations and mixtures thereof are all encompassed by the present invention.
[0346] It will be understood by those skilled in the art that compounds may have tautomeric forms (e.g., keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those depicted in the structural formulas used herein, and that the structural formulas encompass such tautomeric forms, resonance forms, or zwitterionic forms.
[0347] "Pharmaceutically acceptable ester" means an ester that hydrolyzes in vivo (e.g., in the human body) to produce the parent compound or its salt or that itself has an activity similar to that of the parent compound. Suitable esters include C1-C5 alkyl, C2-C5 alkenyl or C2-C5 alkynyl esters, especially methyl, ethyl or n-propyl esters.
[0348] "Pharmaceutically acceptable salt" means a salt of a compound suitable for use in a pharmaceutical formulation. In the case where the compound has one or more basic groups, the salt may be an acid addition salt, such as sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methylsulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, toluenesulfonate, etc. In the case where the compound has one or more acidic groups, the salt may be a salt such as calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzyl salt, sodium salt, tetramethylammonium salt, etc. Polymorphic crystalline forms and solvates are also encompassed within the scope of the present invention.
[0349] "Subject" refers to an animal, including but not limited to a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" with respect to, for example, a mammalian subject (such as a human) are used interchangeably herein.
[0350] In the context of treating a disease or disorder, the terms "treat," "treating," and "treatment" are intended to include alleviating or eliminating the disorder, disease or condition, or one or more symptoms associated with the disorder, disease or condition; or slowing the progression, spread, or worsening of the disorder, disease or condition, or one or more symptoms thereof. "Treatment of cancer" refers to one or more of the following effects: (1) inhibiting tumor growth to some extent, including (i) slowing and (ii) completely stopping growth; (2) reducing the number of tumor cells; (3) maintaining tumor size; (4) reducing tumor size; (5) inhibiting, including (i) reducing, (ii) slowing, or (iii) completely preventing tumor cell infiltration into peripheral organs; (6) inhibiting, including (i) reducing, (ii) slowing, or (iii) completely preventing metastasis; (7) enhancing anti-tumor immune responses, which can result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing tumor growth, (iv) reducing, slowing, or preventing invasion, and / or (8) alleviating to some extent the severity or number of one or more symptoms associated with the disorder.
[0351] In the formulae of this specification, the wavy line transverse to the bond or an asterisk (*) at the end of a bond indicates a covalent attachment site. For example,
[0352] In-style R is or R is The statement means
[0353] In the formulae of this specification, a bond across an aromatic ring between its two carbons means that the group attached to the bond can be located at any position of the aromatic ring that is made available by removing a hydrogen that is implicitly there (or explicitly there, if drawn). By way of illustration, the following formula:
[0354] represent
[0355] In other notes,
[0356] represent
[0357] and
[0358] represent
[0359] The present disclosure includes all isotopes of atoms occurring in the compounds described herein. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14 C. Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described herein using an appropriate isotopically labeled reagent in place of the unlabeled reagent originally employed. By way of example, C1-C3 alkyl can be undeuterated, partially deuterated, or fully deuterated, and "CH3" includes CH3, 13 CH3, 14 CH3, CH2T, CH2D, CHD2, CD3, etc. In one embodiment, the various elements in the compound are present in their natural isotopic abundance.
[0360] It will be understood by those skilled in the art that certain structures may be drawn in one tautomeric form or the other, such as keto and enol, and that both forms are equivalent.
[0361] Acronyms and abbreviations
[0362] This is a list of acronyms and abbreviations used in this specification and their meanings.
[0363]
[0364]
[0365] References
[0366] Full citations for the following references cited earlier in this specification in an abbreviated manner by first author (or inventor) and date are provided below. Each of these references is incorporated herein by reference for all purposes.
[0367] Akinbobuyi et al., Tetrahedron Lett. 2015, 56, 458, "Facile syntheses of functionalized toll-like receptor 7agonists".
[0368] Akinbobuyi et al., Bioorg.Med.Chem.Lett.2016,26,4246, “Synthesis and immunostimulatory activity of substituted TLR7 agonists.”
[0369] Barberis et al.,US 2012 / 0003298 A1(2012).
[0370] Beesu et al.,J.Med.Chem.2017,60,2084,“Identification of High-PotencyHuman TLR8 and Dual TLR7 / TLR8 Agonists in Pyrimidine-2,4-diamines.”
[0371] et al.,J.Immunol.2007,178,4072,“Natural and SyntheticTLR7Ligands Inhibit CpG-A-and CpG-C-Oligodeoxynucleotide-Induced IFN-αProduction.”
[0372] Bonfanti et al.,US 2014 / 0323441 A1(2015)[2015a].
[0373] Bonfanti et al.,US 2015 / 0299221 A1(2015)[2015b].
[0374] Bonfanti et al.,US 2016 / 0304531 A1(2016).
[0375] Carson et al.,US 2013 / 0202629 A1(2013).
[0376] Carson et al.,US 8,729,088 B2(2014).
[0377] Carson et al.,US 9,050,376 B2(2015).
[0378] Carson et al.,US 2016 / 0199499 A1(2016).
[0379] Chan et al.,Bioconjugate Chem.2009,20,1194,“Synthesis andImmunological Characterization of Toll-Like Receptor 7Agonistic Conjugates.”
[0380] Chan et al.,Bioconjugate Chem.2011,22,445,“Synthesis andCharacterization of PEGylated Toll Like Receptor 7 Ligands.”
[0381] Chen et al.,US 7,919,498 B2(2011).
[0382] Coe et al.,US 9,662,336 B2(2017).
[0383] Cortez and Va,Medicinal Chem.Rev.2018,53,481,“Recent Advances inSmall-Molecule TLR7 Agonists for Drug Discovery”.
[0384] Cortez et al.,US 2017 / 0121421 A1(2017).
[0385] Cortez et al.,US 9,944,649 B2(2018).
[0386] Dellaria et al.,WO 2007 / 028129 A1(2007).
[0387] Desai et al.,US 9,127,006 B2(2015).
[0388] Ding et al.,WO 2016 / 107536 A1(2016).
[0389] Ding et al.,US 2017 / 0273983 A1(2017)[2017a].
[0390] Ding et al.,WO 2017 / 076346 A1(2017)[2017b].
[0391] Gadd et al.,Bioconjugate Chem.2015,26,1743,“Targeted Activation ofToll-Like Receptors:Conjugation of a Toll-Like Receptor 7 Agonist to aMonoclonal Antibody Maintains Antigen Binding and Specificity.”
[0392] Graupe et al.,US 8,993,755 B2(2015).
[0393] Embrechts et al.,J.Med.Chem.2018,61,6236,“2,4-Diaminoquinazolines asDual Toll Like Receptor(TLR)7 / 8 Modulators for the Treatment of Hepatitis BVirus.”
[0394] Halcomb et al.,US 9,161,934 B2(2015).
[0395] Hashimoto et al.,US 2009 / 0118263 A1(2009).
[0396] He et al.,US 10,487,084 B2(2019)[2019a].
[0397] He et al.,US 10,508,115 B2(2019)[2019b].
[0398] Hirota et al.,US 6,028,076(2000).
[0399] Holldack et al.,US 2012 / 0083473 A1(2012).
[0400] Isobe et al.,US 6,376,501 B1(2002).
[0401] Isobe et al.,JP 2004137157(2004).
[0402] Isobe et al.,J.Med.Chem.2006,49(6),2088,“Synthesis and BiologicalEvaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as PotentInterferon Inducers.”
[0403] Isobe et al.,US 7,521,454 B2(2009)[2009a].
[0404] Isobe et al.,US 2009 / 0105212 A1(2009)[2009b].
[0405] Isobe et al.,US 2011 / 0028715 A1(2011).
[0406] Isobe et al.,US 8,148,371 B2(2012).
[0407] Jensen et al.,WO 2015 / 036044 A1(2015).
[0408] Jones et al.,US 7,691,877 B2(2010).
[0409] Jones et al.,US 2012 / 0302598 A1(2012).
[0410] Kasibhatla et al.,US 7,241,890 B2(2007).
[0411] Koga-Yamakawa et al.,Int.J.Cancer 2013,132(3),580,“Intratracheal andoral administration of SM-276001:A selective TLR7 agonist,leads to antitumorefficacy in primary and metastatic models of cancer.”
[0412] Li et al.,US 9,902,730 B2(2018).
[0413] Lioux et al.,US 9,295,732 B2(2016).
[0414] Lund et al.,Proc.Nat’l Acad.Sci(USA)2004,101(15),5598,“Recognition ofsingle-stranded RNA viruses by Toll-like receptor 7.”
[0415] Maj et al.,US 9,173,935 B2(2015).
[0416] McGowan et al.,US 2016 / 0168150 A1(2016)[2016a].
[0417] McGowan et al.,US 9,499,549 B2(2016)[2016b].
[0418] McGowan et al.,J.Med.Chem.2017,60,6137,“Identification andOptimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7(TLR7)SelectiveAgonists for the Treatment of Hepatitis B.”
[0419] Musmuca et al.,J.Chem.Information&Modeling 2009,49(7),1777,“Small-Molecule Interferon Inducers.Toward the Comprehension of the MolecularDeterminants through Ligand-Based Approaches.”
[0420] Nakamura et al.,Bioorg.Med.Chem.Lett.2013,13,669,“Synthesis andevaluation of 8-oxoadenine derivatives as potent Toll-like receptor agonistswith high water solubility.”
[0421] Ogita et al.,US 2007 / 0225303 A1(2007).
[0422] Ota et al.,WO 2019 / 124500 A1(2019).
[0423] Pilatte et al.,WO 2017 / 216293 A1(2017).
[0424] Poudel et al.,US 10,472,361 B2(2019)[2019a].
[0425] Poudel et al.,US 10,494,370 B2(2019)[2019b].
[0426] Poudel et al.,US 2020 / 0038403 A1(2020)[2020a].
[0427] Poudel et al.,US 2020 / 0039986 A1 2020)[2020b].
[0428] Purandare et al.,WO 2019 / 209811 A1(2019).
[0429] Pryde,US 7,642,350 B2(2010).
[0430] Sato-Kaneko et al.,JCI Insight 2017,2,e93397,“CombinationImmunotherapy with TLR Agonists and Checkpoint Inhibitors Suppresses Head andNeck Cancer”.
[0431] Smits et al.,The Oncologist 2008,13,859,“The Use of TLR7 and TLR8Ligands for the Enhancement of Cancer Immunotherapy”.
[0432] Vasilakos and Tomai,Expert Rev.Vaccines 2013,12,809, "The Use of Toll-like Receptor 7 / 8Agonists as Vaccine Adjuvants".
[0433] Vernejoul et al., US 2014 / 0141033 A1(2014).
[0434] Young et al., US 10,457,681 B2(2019).
[0435] Yu et al.,PLoS One 2013,8(3),e56514, "Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular DockingStudies."
[0436] Zhang et al., Immunity 2016, 45, 737, “Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-StrandedRNA.”
[0437] Zhang et al.,WO 2018 / 095426 A1(2018)>
[0438] Zurawski et al., US 2012 / 0231023 A1(2012).
[0439] The foregoing detailed description includes paragraphs that are primarily or exclusively related to a particular part or aspect of the present invention. It should be understood that this is for clarity and convenience, that a particular feature may be relevant in more than just the paragraphs that disclose it, and that the disclosure herein includes all appropriate combinations of information found in different paragraphs. Similarly, although the description herein relates to a specific embodiment of the present invention, it should be understood that where a specific feature is disclosed in the context of a specific embodiment, such a feature may also be used in the context of another embodiment, in combination with another feature, or in the present invention as a whole to an appropriate degree.
[0440] Furthermore, while the invention has been specifically described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.
Claims
1. A compound having a structure according to formula (Ia) in R 1 Selected from Each R 2 Independently O(C 1 -C 3 Alkyl), S(C 1 -C 3 alkyl), O(C 3 -C 4 Cycloalkyl) or S(C 3 -C 4 Cycloalkyl), wherein C 1 -C 3 The alkyl group is optionally substituted with one or more halo substituents; R 4 yes and R 5 It is H or Me.
2. The compound according to claim 1, which has a structure according to formula (Ib):
3. A compound selected from:
4. Use of a compound according to any one of claims 1 to 3 in the preparation of a medicament for use in a method of treating cancer, the method comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapeutic agent and a compound according to any one of claims 1 to 3.
5. The use according to claim 4, wherein the anti-cancer immunotherapeutic agent is an antagonistic anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody.
6. The use according to claim 4, wherein the cancer is lung cancer, pancreatic cancer, kidney cancer, head and neck cancer, lymphoma, skin cancer, urothelial carcinoma, gastric cancer, hepatocellular carcinoma or colorectal cancer.
7. The method of claim 4, wherein the cancer is non-small cell lung cancer, Hodgkin's lymphoma, melanoma, Merkel skin cancer or bladder cancer.
8. The use according to claim 6 or 7, wherein the anti-cancer immunotherapeutic agent is ipilimumab, nivolumab or pembrolizumab.
Citation Information
Patent Citations
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
US20200038403A1
Purine derivative
US6028076A
Gun sight featuring point-to-point alignment
US7451566B1
Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
WO2018095426A1
6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like receptor 7 (TLR7) agonists
WO2019035971A1
